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The aim of this study was to complete a pilot project to ascertain if the research 
design was appropriate to determine whether a daily oral dose of probiotics can 
reduce the rate of vaginal group B streptococcal (GBS) colonisation in pregnancy.   
Methodology  
A pilot randomised controlled trial was performed which recruited 34 GBS-positive 
women who were approximately 36 weeks pregnant.  The participants were 
randomly allocated to the control group, who continued with standard antenatal care, 
or to the intervention group, which continued with standard antenatal care and 
received a daily oral dose of probiotics for three weeks or until the birth of their 
infant.  A lower vaginal swab to detect the presence of GBS was collected three 
weeks post consent or when a participant was in labour.   
Results 
No significant difference was found in vaginal GBS rates between the control and 
intervention groups.  Only seven of 21 women in the intervention group completed 
the entire 21 days of probiotics.  A subgroup analysis, including only those who had 
completed 14 days or more of probiotics (n=16), also showed no significant 
difference in vaginal GBS when compared to the control.  As a secondary finding of 





There are five possible reasons for the lack of significant results: 
 The length of the intervention was too short. 
 The dosage of the probiotics was too low. 
 The wrong strains of probiotics were used. 
 The sample size was inadequate. 
 Oral probiotics are ineffective in impacting vaginal GBS. 
Implications 
The secondary finding of a significant increase of vaginal commensals (normal 
vaginal flora, including Lactobacilli) in women who completed 14 days or more of 
probiotics supports the potential of probiotics to impact GBS in pregnancy.  The 
presence of commensals should be included as an indicator in future research 
projects.  This pilot project has provided no evidence that probiotic use in later 
pregnancy is unsafe.  Many possibilities remain for future research to further 
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1   INTRODUCTION 
1.1 Background 
Group B streptococcus (GBS) is a bacterium that colonises the vaginas of 15 to 
25 per cent of pregnant Australian women (McIlwaine et al., 2006; Royal Australian 
and New Zealand College of Obstetricians and Gynaecologists, 2012).  This 
bacterium is the leading cause of infections in newborns in the developed world 
(Centers for Disease Control and Prevention, 2010; Columbo et al., 2006; Ohlsson & 
Shah, 2013).  It can be passed from a woman to her newborn during the process of 
labour and birth and has the potential to result in pneumonia, septicaemia and 
meningitis in the infant (Centers for Disease Control and Prevention, 2010; Columbo 
et al., 2006; Hassan et al., 2011; Jones et al., 2006; Matsubura et al., 2007; Ohlsson 
& Shah, 2013; Valkenburg-van den Burg et al., 2006). 
Presently across Australia, prenatal GBS screening and prophylaxis are widely 
practised, though there is considerable variation in strategies between hospitals 
(Angstetra et al., 2007; Connellan & Wallace, 2000; Hiller et al., 2005; May et al., 
2005). These strategies aim to identify women who are at risk of transmitting GBS to 
their infants.  These at-risk women are given intravenous antibiotics in labour to 
inhibit the transmission (Royal Australian and New Zealand College of Obstetricians 
and Gynaecologists, 2012; Reingold et al., 2007).  As a result of intrapartum 
antibiotic prophylaxis, the incidence of early onset neonatal GBS disease in 
Australasia fell from 1.43 per 1000 live births in 1993 to 0.25 per 1000 live births in 
2001 (Daley & Isaacs, 2004).  However, there are disadvantages associated with the 
use of intravenous antibiotics.  
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The disadvantages of giving intravenous antibiotics in labour include the 
development of antibiotic resistance in GBS and other bacteria, and the disruption of 
the early growth of good bacteria in the newborn’s gut (Baltimore, 2007; Centers for 
Disease Control and Prevention, 2010; Cheng et al., 2006; Daley & Isaacs, 2004; 
Edwards, 2006; Grimwood et al., 2002; Ohlsson & Shah, 2013; Pattern et al., 2006; 
Rautava et al., 2012; Russel & Murch, 2006).  In the United States and Canada, 20 to 
35 per cent of labouring women now receive intravenous antibiotic prophylaxis 
(Baltimore, 2007; Centers for Disease Control and Prevention, 2010; Chen et al., 
2005; Glasglow et al., 2005; Pattern et al., 2006).   
It has been proven by many research studies that women with higher vaginal 
colonisations of Lactobacillus are more likely to have no detectable vaginal GBS 
colonisations (Altoparlak et al., 2004; Donders et al., 2000; Kubota et al., 2002; 
Takeyoshi et al., 2002; Whitney et al., 2004).  This finding generates the hypothesis: 
could increasing Lactobacillus colonisation rates in pregnant women’s vaginas 
decrease GBS colonisation rates?  One possible means of increasing the 
Lactobacillus colonisation in women’s vaginas may be through the use of probiotics.  
1.2 Aim 
The aim of this study was to complete a pilot to ascertain if the research design was 
appropriate to determine whether a daily oral dose of probiotics can reduce the rate 
of vaginal group B streptococcal (GBS) colonisation in pregnant women.   
1.3 Overview of thesis 
 
The intent of this thesis is to give a succinct and understandable description of the 
research that was performed into the impact of oral probiotics on vaginal GBS 
colonisation rates and to provide a clear discussion of the implications of the 
1. Introduction 
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completed study. The introductory chapter of this thesis provides background 
information on the study being presented and an overview of what can be anticipated 
in the following chapters. 
The literature review in Chapter 2 describes the search strategies used to amass the 
scientific information available pertaining to GBS, probiotics and vaginal health.  As 
probiotics are an emerging area of scientific interest, the published data on 
previously completed research studies was limited.  No previous clinical trials were 
discovered that investigated the impact of probiotic use on GBS colonisation rates.  
In reaction to this, the search field was broadened to include completed 
investigations into the impact of probiotics on other vaginal health concerns, such as 
bacterial vaginosis.  The review also correlates the published information on the 
impact of probiotic use by pregnant women, specifically addressing the area of the 
safety of probiotic use in pregnancy. 
Chapter 2 also identifies a gap in the available published scholarly information on the 
impact of probiotics on GBS vaginal colonisation rates in pregnancy.  It highlights 
the need for well-designed, well-powered randomised controlled trials in the area of 
probiotics and vaginal health. 
The methodology and study design of the project are presented in Chapter 3.  In this 
chapter the theoretical framework of a pragmatic approach within a pilot randomised 
controlled trial is described and justified.  The chapter also describes and details the 
methods used to conduct the research, including a description of the study site, study 
population, recruitment strategies, sample size, intervention and observations.  A 
discussion of the data analysis methods utilised and the ethical considerations 
pertaining to this study is also included in Chapter 3. 
1. Introduction 
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The research findings are presented in Chapter 4.  The SPSS computer program was 
utilised as a tool in this chapter to assist with the analysis of the raw data.  Two 
significant findings emerged from the analysis, pertaining to the absence of adverse 
events with the use of probiotics in later pregnancy and the positive potential for 
further studies into the use of oral probiotics to impact vaginal GBS colonisation 
rates.  However, due to the small sample size, the potential for Type 1 errors is 
increased. 
In Chapter 5, the major findings are highlighted and discussed.  The aim of this study 
was to determine the appropriateness of the research design used in this pilot project.  
The discussion chapter focuses on the implications of the results generated by this 
study for future research designs.  It also highlights the strengths of the study and the 
information it has contributed to the growing body of knowledge regarding probiotic 
use to impact the vaginal micro environment. 
Finally, Chapter 6 concludes the thesis.  In this chapter, the aim of the study and the 
major findings are reiterated.  The findings are then reflected upon in light of their 
implications for future research projects and clinical practice. 
2. Literature review 
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2  LITERATURE REVIEW 
2.1 Introduction 
This chapter reviews the current literature pertaining to group B streptococcal (GBS) 
vaginal colonisation and probiotics in pregnancy.  Due to the limited availability of 
information on this topic evidence surrounding probiotics and bacterial vaginosis 
(BV) in both pregnant and non-pregnant women is also included in this review.   
A search was performed of the electronic data bases: Cochrane Library, Expanded 
Academic, Health Reference Centre Academic, Health Sciences, Meditext, Medline, 
Nursing and Allied Health Source, Popline, ProQuest, Sage, Science Direct, Springer 
and Wiley Interscience. The search terms used were ‘probiotics’, pregnan*’, 
‘urogenital’, ‘Group B Streptococc*’, ‘Streptococcus Agalactiae’, and 
‘Lactobacillus’, as found in the abstract.  Additional journal articles were then 
procured by identifying relevant studies in the body and reference lists of articles 
found through the database search.  
The inclusion criteria for the review were any articles pertaining to probiotics and 
pregnancy, probiotics and GBS, or probiotics and BV.  Studies were excluded if they 
focused on urinary tract infections or in vitro experiments. Electronic auto alerts 
were instigated throughout the duration of the study to allow for regular updates of 
emerging literature in this area. 
The bacterium GBS is the leading cause of infections in newborns in the developed 
world (Centers for Disease Control and Prevention 2010; Columbo et al., 2006; 
Hassan et al., 2011; Ohlsson & Shah, 2013).  Fifteen to 25 per cent of pregnant 
Australian women carry GBS in their vaginas (McIlwaine et al., 2006; Royal 
Australian and New Zealand College of Obstetricians and Gynaecologists, 2012).  
2. Literature review 
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The bacteria are passed from a woman to her newborn during the process of labour 
and birth and may result in pneumonia, septicaemia and meningitis in the infant 
(Centers for Disease Control and Prevention, 2010; Columbo et al., 2006; Jones et 
al., 2006; Matsubura et al., 2007; Ohlsson & Shah, 2013; Valkenburg-van den Burg 
et al., 2006).  In Australia, approximately one per cent of maternal GBS carriers will 
infect their infants at birth; of these infants, six per cent will die and many others will 
sustain permanent neurological damage (Centers for Disease Control and Prevention, 
2010; Connellan & Wallace, 2000). 
As stated in the Introduction chapter, due to the severity of neonatal GBS infection, a 
variety of strategies which aim to identify women at risk of transmitting GBS to their 
infants are practised around Australia (Angstetra et al., 2007; Connellan & Wallace, 
2000; Hiller et al., 2005; May et al., 2005). These at-risk women are given 
intravenous antibiotics in labour to assist in inhibiting the transmission of GBS to the 
neonate (Reingold et al., 2007; Royal Australian and New Zealand College of 
Obstetricians and Gynaecologists, 2012).  However, there are disadvantages 
associated with the use of intravenous antibiotics.  
The disadvantages of giving intravenous antibiotics in labour include the 
development of antibiotic resistance in GBS and other bacteria, and the disruption of 
the early growth of good bacteria in the newborn’s gut (Baltimore, 2007; Centers for 
Disease Control and Prevention, 2010; Cheng et al., 2006; Daley & Isaacs, 2004; 
Edwards, 2006; Grimwood et al., 2002; Gronlund et al., 2011; Ohlsson & Shah, 
2013; Pattern et al., 2006; Rautava et al., 2012; Russel & Murch, 2006).   
Many studies are available which have shown that women with higher vaginal 
colonisations of Lactobacillus are more likely to have no detectable vaginal GBS 
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colonisations (Altoparlak et al., 2004; Donders et al., 2000; Kubota et al., 2002; 
Takeyoshi et al., 2002; Whitney et al., 2004).  These findings form the basis of this 
study.  Can we impact the vaginal colonisation of GBS by manipulating the 
Lactobacilli colonisation? One means of facilitating this manipulation process may 
be through the use of probiotics.  
This review of the literature has identified that there is a gap in the research on the 
impact of probiotic usage on GBS vaginal colonisation in both pregnant and non-
pregnant individuals.  As a result, this review focuses mainly on related studies 
investigating the impact of different probiotic strains on the incidence of bacterial 
vaginosis, which, like GBS, is a bacterial infection of the vagina.  The review also 
summarises the available research surrounding the safety of probiotic use in 
pregnancy.  Safety is an important issue which must be addressed prior to 
undertaking research due to its obvious implications for future research, particularly 
research into the impact of probiotics in pregnancy on GBS vaginal colonisation 
rates.  The next section defines the term ‘probiotic’ in order to assist in clarifying the 
use of this word in the literature as opposed to the broader colloquial term used in 
mainstream marketing.   
2.2 Probiotics 
Probiotics are defined as ‘live microorganisms which, when administered in adequate 
amounts, confer a health benefit to the host’ (World Health Organisation, 2002). 
Probiotics are readily available ‘over the counter’ in Australia.  They are contained in 
many dairy products, such as yoghurt, consumed daily by pregnant women.  
Anecdotally, probiotics have been used by midwives for many years to manage GBS 
in pregnancy, though no research studies have been performed to determine their 
2. Literature review 
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effectiveness (Murry, 2002).  Additionally, there are many websites extolling the 
benefits of yoghurt with live cultures and probiotics for vaginal health.   
Lactobacilli are one such probiotic microorganism.  Lactobacilli are the primary 
organisms in the vaginas of healthy women.  Their colonisation of the vagina has 
been shown to reduce the incidence of bacterial vaginosis, yeast vaginitis, urinary 
tract infections and sexually transmitted diseases (Ehrstrom et al., 2010; Marcone et 
al., 2010; Reid, 2008; Reid & Bocking, 2003; Zarate & Nader-Macias, 2006).  
Similar to many urogenital infections, Lactobacilli colonise the vagina mainly 
through ascension across the perineum from the rectum to the vagina (Reid & 
Bocking, 2003; Lagenaur et al., 2011a).  
In contrast to the advantages of naturally occurring Lactobacillus, many of the 
current commercially available strains of probiotics raise concerns regarding their 
efficiency in producing purported health benefits.  The documented concerns relating 
to this category of probiotics are that companies can make unsubstantiated claims, 
the products can contain dead or unreliable probiotic contents, they can contain 
inadequate numbers of probiotic strains, and they can have a poor shelf life (Reid, 
2008; Reid et al., 2003; Senok, 2005). In order for an oral probiotic to be effective, it 
must be able to survive passage through the gastro-intestinal tract.  It must be able to 
proliferate and colonise the digestive tract. It must be safe and effective, and it must 
maintain its effect for the duration of the shelf life of the product (Barrons & 
Tassone, 2008, Senok et al., 2005; Zarate et al., 2005).  
In addition to these concerns, the effects of probiotics have been shown to be strain 
specific; therefore, the use of an individual micro-organism strain is only justified in 
procuring the specific benefits that it has been proven to convey (Martinez et al., 
2. Literature review 
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2009; Pham et al., 2008, World Health Organisation, 2002).  For example, a specific 
strain of Lactobacilli which has been proven to improve travellers’ diarrhoea cannot 
also be assumed to improve eczema.  Each strain and its benefits need to be 
determined individually.  Another challenge surrounding probiotics is that in vitro 
experiments do not necessarily translate to real-life health benefits in human and 
animal models.  As a result, it is necessary for individual specific strains to have been 
proven in clinical trials in order to confirm their ability to produce specific health 
outcomes in humans before beneficial claims can be made (Reid, 2008; World 
Health Organisation, 2002). 
2.3 Probiotics and bacterial vaginosis 
There was no literature found specifically investigating the impact of probiotics on 
the vaginal colonisation rate of GBS in either pregnant or non-pregnant women.  One 
area which has been investigated is the impact of probiotics on bacterial vaginosis.  
Bacterial vaginosis (BV) is an overgrowth in the vagina of various anaerobic 
bacterial species.  It is associated with endometriosis, pelvic inflammatory disease, 
complications of pregnancy and an increased risk of sexually transmitted diseases 
(Reid et al., 2004; Wang et al., 2010).  The studies discovered have shown promising 
results regarding the impact of different strains of Lactobacilli on the incidence of 
BV, both as a therapy in themselves and as an adjunct to antibiotic treatment.  The 
following section of this review presents the available research on probiotics and BV, 
as classified by the specific probiotic strains presented in the literature.   
2.3.1 Lactobacillus rhamnosus GR-1 and fermentum/reuteri RC-14 
The combination of probiotic strains Lactobacillus rhamnosus GR-1 (GR-1) and 
Lactobacillus fermentum/reuteri RC-14 (RC-14) has undergone much research with 
2. Literature review 
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regard to BV.  Four trials have been completed that investigated the oral 
effectiveness of GR-1/RC-14 to alter vaginal flora.  One study by Reid et al. (2001) 
involving 42 healthy female participants randomly assigned each woman to one of 
four different treatment groups.  There was no control in this study.  Three groups 
were given GR-1/RC-14 in different dosages.  The fourth group was given a different 
strain of probiotics, Lactobacillus rhamnosus GG.  It was found that a daily oral dose 
of more than 10
8
 culture-forming units (cfu) of GR-1/RC-14 restored and maintained 
healthy vaginal micro flora.  No improvements were noted in the L. rhamnosus GG 
group (Reid et al., 2001). Two other studies randomly allocated 64 (Reid et al., 2003) 
and 59 (Reid et al., 2004) healthy women respectively to receive either a daily oral 
dose of GR-1/RC-14 (>10
9 
cfu) or a placebo for 60 days.  Both studies showed 
significant improvement in the vaginal micro flora in the intervention group, with 
increased Lactobacilli colonisation and decreased yeast and coliform infections 
compared to the control (Reid et al., 2003; Reid et al., 2004).  A fourth study 
(Anukam et al., 2006a) randomly allocated 40 participants diagnosed with BV either 
to insert vaginally two gelatine capsules of GR-1/RC-14 (10
9
 cfu) daily for five days 
or to apply the antibiotic Metronidazole in vaginal cream twice daily for five days.  
Post follow-up on days six, 15 and 30, this study showed BV was cured in 
significantly more probiotic-treated participants compared with the antibiotic-treated 
participants (Anukam et al., 2006a).  These studies indicate that the Lactobacillus 
strains RC-14 and GR-1 have the potential to impact vaginal health. The drawbacks 
of each of these studies were the small sample sizes and the lack of reporting of 
power calculations in each of the journal articles.   
Two studies (Anukam et al., 2006b; Martinez et al., 2009) have also been undertaken 
to demonstrate the effectiveness of GR-1/RC-14 (10
9
 cfu) as an adjunct treatment to 
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antibiotic therapy for BV.  In the first study by Anukam et al. (2006b), which 
involved 106 women diagnosed with BV, all the participants were given an oral dose 
of the antibiotic Metronidazole twice daily for seven days.  The participants 
randomised into the treatment group were then given oral GR-1/RC-14 twice daily 
for 30 days and the control group was given a placebo twice daily for 30 days.  After 
30 days, 88 per cent of the treatment group no longer had BV.  It was interesting to 
note that in contrast, 40 per cent of the placebo group no longer had BV. 
Similarly, a study by Martinez et al. (2009) involving 64 women diagnosed with BV 
treated every participant with a single dose of Tinidazole.  They were then randomly 
assigned to the treatment or control group.  The treatment group was given two oral 
capsules of GR-1/RC-14 (10
9
 cfu) daily for 28 days. The control group, on the other 
hand, was given two placebo capsules daily for 28 days.  On day 28, there was an 
87.5 per cent cure rate for BV in the treatment group versus a 50 per cent cure rate in 
the control group.  These studies indicate that the use of these probiotic strains can 
aid in the prevention of relapses of BV post antibiotic treatment.  These results are in 
addition to their potential as a treatment for BV independent of antibiotics.   
2.3.2 Lactobacillus acidophilus 
Another strain of lactobacillus that has been investigated with regard to BV is 
Lactobacillus acidophilus.  One study (Hallen et al., 1991) randomly allocated 




 cfu) in vaginal 
suppositories two times daily for six days, or a placebo.  Follow-up immediately after 
treatment found that 57 per cent of the probiotic group had normal findings while the 
entire placebo group still had BV.  No further follow-up was possible, as 22 of the 
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participants who still had BV required treatment with antibiotics after the first 
follow-up visit (Hallen et al., 1991).   
A study by Drago et al. (2007) treated 40 BV-infected women with an L. acidophilus 
douche (10
9
 cfu/ml) for six days.  There was no control group in this study.  It found 
that, post treatment, 30 of the participants had improved vaginal Lactobacilli counts, 
while three participants remained unchanged and seven had decreased Lactobacilli 
counts.  Twenty to 23 days after the completion of treatment, it was found that the 
increased Lactobacilli counts persisted in 29 of the participants.  A third study also 
claimed a clear increase in the colonisation of the rectum and vagina with 
L. acidophilus and a significant reduction in the occurrence of BV after women 
ingested culture-containing yoghurt for two months versus ingesting pasteurised 
yoghurt for two months (Shalev et al., 1996).  The validity of these claims needs to 
be viewed with caution due to the extremely high attrition rate experienced in the 
study.  Another study (Delia et al., 2006), without a control group, administered 
vaginal suppositories with L. acidophilus to 60 women with suspected or confirmed 
BV. This study found vaginal Lactobacilli to be a successful treatment for BV.  
Though these studies trend towards indicating that Lactobacillus acidophilus has the 
potential to positively impact vaginal Lactobacilli colonisation, their lack of control 
groups, high attrition rates and small sample sizes bring each of the individual 
findings into question. 
A final study (Ozkinay et al., 2005) involving L. acidophilus recruited 360 women 
with vaginal infections.  After receiving anti-infective treatment, the participants 
were randomly allocated to receive either a vaginal tablet containing a minimum of 
10
7
 cfu of L. acidophilus and Oestriol daily for six days, or a placebo.  This study 
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found a significantly higher improvement in the vaginal ecology of participants in 
the probiotics group versus the control group.  This study adds to the argument of the 
aforementioned research that Lactobacillus acidophilus is another strain of probiotics 
with the potential to impact the micro flora of the vagina. 
2.3.3 Other strains of Lactobacillus 
In contrast to the positive findings of the studies mentioned, a study by Eriksson et 
al. (2005) found no significant difference in outcome rates between its probiotic and 
placebo groups.  This study randomly assigned women with BV to the intervention 
group or to the control group after a course of Clindamycin.  The intervention group 





 cfu) during menstruation.  The control group used a placebo.  No significant 
improvement was noted between the two groups.  Another study (Larsson et al., 
2008) was performed which showed no significant difference in outcome rates 
between the probiotics and placebo groups.  In this study, women with BV were 
randomly assigned, after a course of Clindamycin, to use vaginal capsules containing  




 cfu) for 10 days or a placebo.  Both 
these studies highlight that clinical results are specific to individual probiotic strains.  
This emphasises the importance of choosing the appropriate strains and dosages of 
probiotics when trying to elicit a specific health benefit in the micro environment of 
the vagina. 
A final study (Ronnqvist et al., 2006) is of note because it is the only one to make 
mention of GBS.  In this study, 176 healthy, fertile women were randomly assigned 
to wear vapour-permeable panty liners impregnated with Lactobacillus plantaron 
(>5*10
8 
per panty liner) 24 hours a day for four consecutive menstrual cycles or to 
2. Literature review 
  14 
 
use a placebo.  This study found that, post treatment, Lactobacilli were found in the 
labial samples of 86 per cent and in the vaginal samples of 54 per cent of women in 
the probiotics group, but it did not show any significant decrease in the presence of 
microbes.  The study population had an extremely high prevalence of GBS among its 
participants, with a 43 per cent GBS carrier rate.  It reported that women with a high 
number of Lactobacillus in their vaginas had a 17 per cent prevalence of GBS but the 
use of panty liners impregnated with Lactobacillus plantaron did not lower the GBS 
carrier rate.  This is the only study that reported on the impact of such an intervention 
on GBS.  The results of this study highlight the need for further research to identify 
whether a strain of Lactobacillus exists that would be effective in reducing GBS 
colonisation rates in women, specifically in pregnancy. 
The following section reports on the research conducted involving probiotic use in 
pregnancy.  It focuses mainly on the use of probiotics in pregnancy to impact BV and 
the safety of probiotic use in pregnancy. 
2.4 Probiotics in pregnancy 
The clinical trials that have been completed investigating the impact of probiotics in 
pregnancy have focused mainly on the use of oral probiotics to prevent the 
development of atopic eczema in infants.  No published studies were identified that 
reported on the impact of probiotics on GBS vaginal colonisation rates in pregnancy.  
In a related field, four studies (Krauss-Silva et al., 2011; Neri et al., 1993; Nishijima 
et al., 2005; Thiagarajan, 1998) have investigated the impact of a daily dose of 
probiotics, administered either orally or vaginally, on rates of bacterial vaginosis 
specifically in pregnant women.   
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One of these studies (Nishijima et al., 2005) randomly assigned 24 pregnant women 
to receive either a daily dose of Lactobacillus jonsonii (10
9
 cfu) or a placebo milk 
drink for two weeks.  The study discovered that the consumption of this probiotic 
drink significantly increased the number of vaginal Lactobacilli and showed a trend 
towards a decrease in BV pathogens.  Another study (Thiagarajan, 1998) randomly 
assigned 381 pregnant women with BV in their first trimester of pregnancy to receive 
either an intravaginal dose of yoghurt twice daily for one week or an intravaginal 
placebo.  This study found that yoghurt was two-thirds as effective as antibiotics for 
treating BV, as measured by the persistence or absence of BV indicators. A study by 
Neri et al. (1993) randomly assigned 84 women with BV in their first trimester of 
pregnancy to receive either yoghurt vaginal douching (L. acidophilus >10
8
/ml) or 
acetic acid tampons twice daily for seven days.  This study showed an 87.5 per cent 
clinical improvement rate at one and two months post treatment in the yoghurt group 
versus a 37.5 per cent clinical improvement rate in the acetic acid group.   
A final study by Krauss-Silva et al. (2011) randomised 644 women in their second 
trimester of pregnancy to receive orally either two capsules of GR-1/RC-14 (10
9 
cfu) 
or a placebo for six to 12 weeks.  Sixty-two per cent of the women recruited 
completed the study.  The aim of the study was to determine the impact of 
administering oral probiotics to women in early pregnancy with asymptomatic BV on 
premature delivery rates.  Unfortunately, the trial was unable to be completed due to 
resource restraints and had an insufficient study sample to estimate any statistically 
significant effects.  However, this study did not report any safety concerns with the 
use of GR-1/RC-14 in its pregnant participants.  
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These studies indicate the positive potential of probiotics to impact the vaginal micro 
ecology in not only non-pregnant women but pregnant women as well. When 
broaching the area of the therapeutic use of probiotics in pregnancy safety is an 
obvious concern.  The following section addresses this concern, presenting the 
available research pertaining to probiotic use and safety considerations in pregnancy.   
2.5 Safety considerations 
Are probiotics safe for the mother and the developing foetus when used in 
pregnancy?  Probiotics are strain dependent and their safety needs to be determined 
on a strain by strain basis (Liong, 2008).  Infections caused by Lactobacilli are 
extremely rare in the general non-pregnant population. They have been implicated in 
approximately 0.05 to 0.4 percent of combined cases of infective endocarditis and 
bacteraemia.  Most of these infections occurred in individuals with chronic diseases 
or debilitating conditions such as recent surgery, organ transplant, valvulopathy, 
diabetes mellitus, AIDS, acute pancreatitis and cancer (Barrons & Tassone, 2008; 
Besselink et al., 2008; Boyle et al., 2006; Liong, 2008; Pham et al., 2008; World 
Health Organisation, 2002). In light of this, it is necessary to monitor all strains for 
potential adverse side-effects (Allen et al., 2010). 
The studies mentioned earlier in this review, involving both healthy non-pregnant 
and pregnant women, all reported mild, transient and rare adverse effects from 
probiotic use.  The most serious side-effect reported involved two cases of persistent 
headache for the first three days of probiotic treatment in a sample of 106 non-
pregnant participants (Anukam et al., 2006b).   
When specifically considering the safety of probiotic use in pregnancy, there have 
been other studies performed investigating probiotic use in pregnancy in relation to 
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blood glucose control and the development of atopic eczema in infants.  None of 
these studies reported any adverse side effects in their total combined 984 pregnant 
participants (Doege et al., 2012; Kalliomaki et al., 2001; Lahtinen et al., 2009; Leiten 
et al., 2008; Luoto et al., 2010; Schultz et al., 2004; Wickens et al., 2008).  One study 
(Allen et al., 2010) traced adverse outcomes post-probiotic administration in 
pregnancy until the infants were six months of age.  In this study, pregnant women in 
their last trimester of pregnancy were randomly allocated to receive Bifidobacterium 
and Lactobacillus salivarius and paracasei (10
9
 cfu) daily or to receive a placebo.  
This study found that, of the 220 mother-infant dyads in the treatment group, the 
reported adverse events did not differ significantly from the placebo group. (Allen et 
al., 2010).   
In order to further investigate the safety of probiotic use in pregnancy, Dugoua et al. 
(2009) performed a meta-analysis of the available randomised controlled trials to 
ascertain specifically the safety of Lactobacillus, Bifidobacterium and 
Saccharomyces spp. during pregnancy.  In total, eight studies met the inclusion 
criteria. The meta-analysis indicated that administering certain strains of 
Lactobacillus spp. and Bifidobacterium spp. did not have any effect on caesarean 
section rate, birth weight, gestational age or birth malformations.  There was not 
enough evidence to determine the safety of Saccharomyces spp. in pregnancy.   
In summary, the studies to date have shown no major adverse events in healthy non-
pregnant and pregnant participants.  It is imperative to stress that each strain is 
specific in its health benefits and health concerns. Therefore, it is particularly 
important to continue monitoring for the adverse effects of each specific strain of 
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probiotics, particularly when involving vulnerable population groups such as 
pregnant women. 
2.6 Conclusion 
In conclusion, this review has shown that there is adequate evidence in the literature 
to indicate the potential for different probiotic strains to positively impact vaginal 
ecology.  Group B streptococcus is a bacterium that causes major health risks for 
birthing infants when it colonises women’s vaginas in pregnancy.  Through a review 
of the literature, it is apparent that a gap in the evidence exists regarding the impact 
of individual probiotic strains on the GBS vaginal colonisation rates of pregnant 
women.  The discovery of such a beneficial strain would contribute to the 
development of strategies for the prevention GBS vaginal colonisation in pregnant 
women, thereby reducing the need for intravenous antibiotics in labour while 
ensuring the safety of birthing infants.  In this quest to discover an appropriate strain 
of probiotic to combat GBS, it remains important to recognise the potential for 
adverse side-effects of probiotics and to be vigilant in monitoring for any safety 
issues that may arise while investigating probiotic use in pregnancy. 
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3  RESEARCH DESIGN 
3.1 Introduction  
As stated in the literature review chapter, research has consistently shown that 
women with higher vaginal colonisations of Lactobacillus are more likely to have no 
detectable vaginal GBS colonisations (Altoparlak et al., 2004; Donders et al., 2000; 
Kubota et al., 2002; Takeyoshi et al., 2002; Whitney et al., 2004).  One potential 
means of manipulating Lactobacillus concentrations in order to attempt to impact the 
GBS colonisation rates is through the use of probiotics.  The aim of this study was to 
complete a pilot project to ascertain whether the research design was appropriate to 
determine if a daily oral dose of probiotics can reduce the rate of vaginal group B 
streptococcal (GBS) colonisation in pregnancy.   
The following chapter outlines and justifies the theoretical frameworks and the 
research design used while conducting this research project.  It also explains the 
ethical issues surrounding the research methods and the intervention used. 
3.2 Theoretical framework for the methodology 
This section outlines and justifies the decision to utilise a pilot randomised controlled 
trial (RCT) framework as the major method for this study.  It also describes and 
explains how a pragmatic approach was implemented within the RCT design in order 
to increase the applicability and comprehensibility of the study results.   
3.2.1 Quantitative methods 
A pilot RCT was chosen as the research method for this study.  The main aim of the 
study was to ascertain whether the research design would be appropriate to explore 
potential causal relationships between oral probiotic use and GBS vaginal 
colonisation rates in pregnant women.  The RCT has been identified as the research 
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method which provides the highest level of evidence for determining the presence of 
causal relationships and the effects of an intervention (Peat, 2001; Steen & Roberts, 
2011).  The features of an RCT include random allocation to control and intervention 
groups, double blinding as possible and identical treatment for both groups except for 
the intervention being tested (Hoffmann et al., 2013; Sibbald & Roland, 1998).   
The key aspect of RCT is the randomisation process.  This process serves to allocate 
each participant to a group in an unbiased manner, thereby limiting the influences of 
selection bias and known and unknown confounders (Hoffmann et al., 2013; Peat, 
2001).  In this study, once a participant had met the inclusion criteria and had 
consented to involvement in the study, the participant was randomly allocated to 
either the control or intervention group.  Randomisation assisted in controlling for 
any confounding factors that may have been present in the two different groups of 
participants.   
Another aspect to an RCT that assists in controlling for bias is the process of blinding 
(Hoffmann et al., 2013; Sibbald & Roland, 1998).  In this study, there was no 
placebo; therefore, the researcher and the participants both knew the arm of the study 
to which the participants belonged.  However, the pathologists analysing the swabs 
were blinded to each participant’s allocation in the trial. This ensured that there was 
no bias in the formulation of the results of the vaginal swabs.  The fact that the 
pathologists analysing the swabs were unaware of the group allocation alleviates 
concerns regarding bias in the study and contributes further confidence to the final 
results generated.  
Both the control and intervention groups continued to receive standard care in the 
antenatal clinic throughout the duration of the study.  The only difference that existed 
between the care received was that the intervention group was given a daily oral dose 
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of probiotics for three weeks.  Since both groups were receiving comparable care, 
any differences noted in the final analysis could be justifiably attributed to the 
intervention. 
Finally, a pilot study was undertaken for this project.  Pilot studies are used to test 
study appropriateness and feasibility (Peat, 2001).  The decision to perform a pilot 
study was influenced by the scope and resource limitations of the project.  A pilot 
study served to determine the appropriateness of the study design and of the 
recruitment strategy prior to committing the time and resources to a large RCT.   
3.2.2 Pragmatic study design 
This study, in addition to the RCT model, embraced a pragmatic approach to 
research.  This approach is based on the fact that the ‘traditional criteria for scientific 
validity do not in themselves guarantee usefulness to practitioners’ (Worren et al., 
2002, p. 1228).  Even if results can be produced in a laboratory, these results do not 
necessarily translate into knowledge that is applicable in real-life settings and useful 
for improving clinical practice.  A pragmatic approach is used to determine whether 
an intervention will be successful when implemented under normal circumstances 
(Steen & Roberts, 2011; Zwarenstein et al., 2008).  Research with probiotics has 
shown that results in vitro do not necessarily translate to intervention successes in 
clinical trials (Reid, 2008; World Health Organisation, 2002).  This emphasises the 
importance of ensuring the effectiveness of probiotic interventions in real-life 
clinical settings prior to declaring their health benefits.   
The influences of a pragmatic approach can be identified in many details of the trial 
design. The researcher did not collect the vaginal swabs for the study but the women 
collected their own swabs, which is the standard means of GBS vaginal swabbing at 
the research site.  To aid in achieving a level of standardisation in swabbing 
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techniques, each woman received the same instructions on how to collect a lower 
vaginal swab.  Each participant collected both her own pre- and post-intervention 
vaginal swabs, which ensured a degree of internal control in swabbing techniques.   
Another design detail where a pragmatic approach was applied was in the pathology 
technique used for determining the presence of GBS.  The standard pathology 
methods for measuring GBS at the study site were used.  One limitation of the 
standard pathology tests is they do not give a quantified amount for the GBS colony 
counts per vaginal swab.  The results only specify the presence of a light, moderate 
or heavy growth of GBS.  These results are not sensitive enough to determine 
whether a slight reduction in GBS colonisation has occurred due to probiotic use but 
they would indicate whether GBS had been eradicated in a woman’s vagina.  The 
swabbing and pathology testing techniques used in this study replicated standard 
procedures at the study site, making the results of this study immediately practically 
applicable in the clinical setting. 
3.3 Conducting the research 
This pilot randomised controlled trial was performed from April 2011 to August 
2011, with a follow-up telephone survey performed from November 2011 to March 
2012. Funding for this project was assisted by a $2000 contribution from the New 
South Wales Nurses and Midwives’ Association’s Edith Cavell Trust. The following 
section describes the details of the recruitment and data collection processes to 
conduct the research, including a description of the study site, study population, 
recruitment strategies, sample size, intervention and observations. 
3.3.1 Study site 
The Sutherland Hospital was selected as the study site.  The Sutherland Hospital is a 
low-risk public birthing unit in the southern suburbs of Sydney, Australia.  At this 
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hospital all women attending the antenatal clinic routinely self-perform a lower 
vaginal swab at 36 weeks gestation.  If a woman’s swab result is GBS positive, she 
then receives intravenous antibiotics in labour.  The vaginal GBS rate at the 
Sutherland Hospital for 2008 was approximately 21 per cent (The Sutherland 
Hospital Obstetrix database, retrieved June 2009). 
3.3.2 Study population 
The selected study population for this research was GBS-positive women attending 
the antenatal clinic at the Sutherland Hospital.  The GBS status of these women was 
determined by the routine, self-collected lower vaginal swab performed at 36 weeks 
gestation.   
The following inclusion criteria were applied: age over 18 years, overall good health 
and a normal, uncomplicated pregnancy.  The exclusion criteria and their rationales 
were as follows: 
 Diabetes: women with gestational diabetes have been shown to have an 
increased risk of being GBS positive in pregnancy (Hakansson & Kallen, 
2008). 
 A previous history of endocarditis/valvular heart disease: non-pregnant 
individuals with these conditions have been shown to be at an increased risk 
of developing sepsis with probiotic use (Boyle et al., 2006). 
 Any medical condition or those who were undergoing any treatment that 
would cause their immune systems to be compromised: non-pregnant 
individuals with these conditions have been shown to be at an increased risk 
of developing sepsis with probiotic use (Boyle et al., 2006). 
If a woman developed an infection at any time during the study, she was withdrawn 
from participation but continued having data collected.   
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In addition, women who had any language barrier that hindered their ability to read 
and understand the provided information, which was in English, were excluded from 
participation.  Women with a language barrier were excluded from the study because 
the resource limitations of the study did not make it possible to engage an interpreter 
for such situations.  As such, it would have been impossible to ensure consent was 
informed, making it unethical to recruit such women. 
3.3.3 Recruitment 
Prior to commencing recruitment, it was important to inform the staff of the pending 
research project.  The obstetric team, antenatal and delivery suite midwives and 
antenatal support staff were informed through on-site educational sessions and 
through one-on-one conversations.  These sessions assisted in increasing the 
awareness of the staff, which helped them to understand the role of the researcher 
and to be able to answer questions from women in the antenatal clinic about the 
research. 
In order to inform pregnant women of this study, posters (Appendix A) were 
displayed in the antenatal clinic at the Sutherland Hospital.  When women attending 
the antenatal clinic were approximately 33 weeks pregnant, they were given a 
participant information sheet and a brochure describing the study and informing them 
of a possible future invitation to participate in the study (Appendices B and F). 
The recruitment process commenced once a woman who met the inclusion criteria 
was determined to be GBS positive at 36 weeks.  The woman then received a phone 
call from the researcher with a formal invitation to participate.  If a woman agreed to 
be involved in the research, she was approached by the researcher the following 
week at her antenatal appointment.  At this time informed consent was obtained 
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(Appendix E).  The woman was then randomly assigned to receive both standard 
care and a daily oral dose of probiotics for three weeks, or to continue with standard 
care with the staff in the antenatal clinic.  The randomisation process was computer 
generated by an online site.  For the women who were assigned to be in the 
intervention group, the probiotics were provided at the time of consent. 
Women were recruited based on the results of their standard lower vaginal swab at 
36 weeks gestation.  This decision capitalised on the results of this standard 
procedure, avoiding additional expenses due to the resource limitations of the study.   
3.3.4 Sample size and randomisation 
A power calculation performed to determine the sample size necessary for a RCT 
determined that a sample size of 217 participants per arm of the study would be 
required to reach a 90 per cent significance rate.  To perform the power calculation, 
the vaginal GBS colonisation rate was assumed to be 21 per cent based on the 
vaginal GBS rate at the study site in 2008 (The Sutherland Hospital Obstetrix 
database, retrieved June 2009). The effect size used was determined G. Reid as 
50 per cent (personal communication, 19 August 2009). The power calculation was 
based on detecting the difference between two proportions using a normal 
distribution approximation. Such a study was unrealistic due to scope and resource 
limitations.  A pilot project was utilised to assist in becoming the basis for future 
power calculations and to determine the feasibility of the research design.  This pilot 
project chose to recruit as many women as possible within the three-month 
recruitment time frame, with a minimum aim of 30 participants.  A total of 34 
women were recruited during this time period.   
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Since the exact number of women who would be recruited was uncertain, a simple 
randomisation method was applied using an online randomisation site to create a 
table which randomised 100 potential participants (Kang et al., 2008).  The numbers 
on the table were covered until a woman gave informed consent to the researcher to 
participate in the study.  At this point the researcher revealed whether the woman 
was assigned to the intervention or control group.  The allocation ratio was intended 
to be 1:1. Unfortunately, since only 34 women were recruited but 100 numbers had 
been randomised, the allocation process was weighted heavily towards the 
intervention group.  As a result, the study ended up with 13 women in the control 
group and 21 women in the intervention group.  For a copy of the CONSORT flow 
diagram, refer to Appendix H. 
Neither the participants nor the researcher were blinded to the group allocation. 
3.3.5 Intervention 
The women who consented to be involved in the research were randomly allocated to 
receive both standard care and a daily oral dose of probiotics Lactobacillus 
rhamnosus GR-1 (GR-1) and Lactobacillus fermentum/reuteri RC-14 (RC-14) in a 
dose of 10
8
 viable strains for three weeks or to continue with standard care.  The 
probiotic strains GR-1 and RC-14 were chosen for use in this study because they are 
the strains that have undergone the most clinical trials with respect to urogenital 
health in women.  They have been found to survive passage through the gastro-
intestinal tract and to colonise the vagina after oral administration (Gardiner et al., 
2002; Morelli et al., 2004).  These strains have been shown to colonise the vagina 
during the second week of oral administration (Morelli et al., 2004).  The 
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justification of a three-week intervention period to impact Lactobacillus colonisation 
of the vagina was based on this finding.   
3.3.6 Observations 
Three weeks post consent and post intervention, the GBS-positive women who were  
recruited into the study self-collected a repeat lower vaginal swab.  This swab was 
given to the researcher or to the health practitioner at their appointment in the 
antenatal clinic.  These swabs were tested in the pathology department, which was 
blinded to group allocation.  If a participant commenced labour or spontaneously 
ruptured her membranes prior to completion of the study, a second lower vaginal 
swab was self-collected upon admission to the delivery suite and analysed by the 
pathology department. 
The researcher also collected demographic data about each woman at the time of 
consent.  These data were to assist in controlling for confounding factors. In order to 
protect the privacy of the participants, all the data collected was de-identified at the 
time of collection.  The medical record numbers of each participant were 
documented with the data in order to allow for verification of any missing or 
ambiguous information upon completion of the trial. The information collected about 
each participant at the time of consent can be categorised into demographics and 





 body mass index (BMI) 
 number of pregnancies 
 number of children 
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 expected date of birth  
 number of weeks pregnant upon entry into the study  
 past history with GBS colonisation 
 the research group to which the woman was allocated.   
At the end of the three-week intervention period, each woman was asked whether she 
had taken any antibiotics during the trial.  The women who received the probiotics 
were also asked how often they had been able to take their daily dose of probiotics 
and whether they had had any adverse reactions or side-effects during the trial.   
After women in the trial had given birth, further information was collected. This 
information can be categorised into maternal labour and birth details and neonatal 
details. It is as follows: 
Maternal labour and birth details 
 the development of pregnancy complications (which included the 
development of infections) 
 the type of birth 
 the occurrence of antibiotic administration in labour 
 the final lower vaginal swab result 
Neonatal details 
 the infant’s birth weight. 
Please refer to the appendix for a diagram of the research design (Appendix C) and a 
copy of the list of the additional data (Appendix D) that was collected about each 
participant. 
Six months post birth, a follow-up telephone survey of the participants was 
performed.  This survey was a requirement of the ethics board for ethics approval.  
The intention of this survey was to aid in collecting further data on the safety of these 
specific probiotic strains in pregnancy.  The survey specifically addressed whether 
the infant had any concerns at birth, which included neonatal GBS infection.  
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Appendix G lists the questions asked at the follow-up telephone survey.  The post-
birth questions were structured following the indicators used in two systematic 
reviews conducted on the safety of probiotic use in pregnancy (Allen et al., 2010; 
Dugoua et al., 2009). 
3.4 Data analysis 
The final vaginal swab results were not revealed until after each woman had given 
birth.  The results of this study, therefore, did not impact on the current management 
of the women participating in the study. These GBS-positive women still received 
intravenous antibiotics in labour, as was hospital policy.  Once the data collection 
phase was complete, all the raw data, including the final vaginal swab results, was 
brought together and entered into the SPSS statistical computer program by the 
researcher.  This process occurred in two stages: firstly, after the initial data 
collection phase was complete and, secondly, after the six-month follow-up 
telephone survey was complete.  The data were then analysed using the SPSS 
statistical program.  This process was assisted by the statistical consulting 
department of the University of Wollongong.  
In order to test whether any differences existed between the intervention and control 
groups, an independent t-test was applied to the continuous demographic data, such 
as age and BMI.  A t-test hypothesis states that the difference in the mean of a 
variable when comparing two groups is equal to zero. The null hypothesis in a t-test 
is that the difference in the means is NOT equal to zero.  In this analysis it was 
decided that if a t-test produced a significance level of greater than 0.05 then the null 
hypothesis could be rejected, indicating that there was no difference between the 
means of a variable when comparing the control and intervention groups.  Therefore, 
if the significance level was >0.05 it would indicate that, with regard to a specific 
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demographic variable, both the probiotic group and standard care group were similar 
(McDonald, 2009).  In order to apply an independent t-test it was assumed that the 
data were normally distributed.  The small sample size made tests of normality, such 
as the Shapiro-Wilk test, in the analysis unreliable.  In order to confirm the use of the 
independent t-test on the continuous data in these findings, the Mann-Whitney test 
was applied to each continuous variable.  The Mann-Whitney test is a non-parametric 
test.  All of the Mann-Whitney tests which were applied to the continuous variables 
in the analysis had non-significant results, as did the independent t-test applied to the 
same variables.  The Mann-Whitney tests therefore verify the results of the t-tests in 
this study (Batterham, personal communication, 2015; Newton & Rudestam, 2013). 
To determine whether associations existed between the two groups, a Fisher’s exact 
test was applied to the categorical data, such as the presence of vaginal GBS.  
Normally a chi square test is used to test correlations but due to the small sample size 
of this study the Fisher’s exact test was deemed more appropriate for this data set.  
With this statistical test, the null hypothesis states that the two variables are 
independent of each other and the alternative hypothesis states that they are NOT 
independent.  If the test applied to the data set produces a significance value of less 
than 0.05 then the null hypothesis can be rejected and it can be assumed that a 
relationship exists between the two variables (McDonald, 2009). 
3.5 Ethics 
Within a description of the methodology used, it is also important to discuss the 
ethical considerations surrounding the study.  This discussion justifies the research 
methods from an ethical point of view, thereby ensuring that the study was 
performed in a way that protected the integrity of the participants and their unborn 
infants.  The following section discusses the ethical issues pertaining to this study 
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and its design.  These issues have been categorised into safety considerations, risk of 
coercion, informed consent and confidentiality.  
Ethics approval for this study was granted by the University of Wollongong’s 
Human Research Ethics Committee (HE 10/306).  Site-specific approval was granted 
through the South Eastern Sydney Local Health Network (SSA/11/STG/39).   
3.5.1 Safety considerations 
The primary ethical concern in this project surrounded the issue of safety 
(Beauchamp & Childress, 2009).  Could daily oral use of probiotics result in any 
harm to the mother or the foetus?  Probiotics comprise organisms that are identical to 
those found in the human gastrointestinal tract and in the vagina.  The available 
research indicates that the risk to pregnant women of developing any infections as a 
result of probiotic use is low and there is no expected risk to the developing foetus  
(Kalliomaki et al., 2001; Lahtinen et al., 2009; Leiten et al., 2008; Liong, 2008; 
Pham et al., 2008; Schultz et al., 2004; Wickens et al., 2008; World Health 
Organisation, 2002).  For a discussion of the issue of probiotic safety in pregnancy, 
please refer to section 2.5, ‘Safety considerations’. 
In order to maintain the safety of the participants, the exclusion criteria for this study 
state that any woman with diabetes, a history of valvular heart disease/endocarditis or 
any condition or treatment causing immune system compromise was unable to 
participate in the study. These are all conditions that have been identified in the 
literature as putting an individual at higher risk of developing infections with 
probiotic use (Boyle et al., 2006).  In addition, the research site was a low-risk 
birthing unit. Therefore, women with major health concerns, including those 
concerns that would put women at higher risk of developing an infection with 
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probiotic use, would have their care transferred to a tertiary hospital.  As a result, the 
potential risk of harm to the study population was minimised. 
Based on the above literature and the low-risk status of the birthing unit where the 
study was performed, the anticipated risk to participants was minimal.  In order to 
further evaluate the safety of the probiotics used in the study, pregnancy details, 
maternal labour and birth details, and neonatal details were collected from each 
participant.  These details assisted to audit whether the intervention negatively 
impacted on any of the participants.  A follow-up telephone survey was also 
performed involving all the participants at six months post-partum in order to 
generate further information on the safety of probiotic use in later pregnancy.  
3.5.2 Risk of coercion 
The researcher was a midwife employed in the antenatal clinic and delivery suite at 
the study site.  To reduce the risk of coercion, in the first three months of the study, 
during the recruitment and initial data collection phases, the researcher did not work 
in the antenatal clinic. This reduced the chance of the researcher being directly 
involved with the care of potential participants.  The result was that researcher did 
not care for any participants during the antenatal stage of their pregnancy.  After 
these three months, the women naturally moved through their pregnancies and were 
admitted to the delivery suite to give birth to their babies. There was a risk that  the 
researcher be involved in the care of participants when they were admitted to 
delivery suite but by this stage in the research, the risk of coercion was minimal 
because recruitment was already completed.   
In addition to not being involved in the antenatal care of potential participants, the 
initial contact of potential participants with the researcher was through a telephone 
call.  During this phone call, women who had been determined to be GBS positive 
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were invited to participate in the study.  The telephone call allowed a woman a 
degree of anonymity if she decided to decline participation which would not be 
present in a face-to-face encounter.  If a woman declined to participate, she was not 
approached again by the researcher to participate in the study.   
It was also specified in the consent form and reiterated verbally at the time of consent 
that women were able to withdraw participation consent at any time during the study 
without ramifications for the care they received throughout their pregnancies.  All 
these factors combined to ensure the risk of coercion to potential participants was 
minimised. 
3.5.3 Informed consent 
In this study, the participants were required to sign a consent form. All pregnant 
women were given an information sheet when they were 33 weeks pregnant 
(Appendices B and F).  GBS-positive women who indicated an interest in 
participating in the study over the telephone were approached the following week in 
the antenatal clinic by the researcher.  At this time, informed consent was sought 
(Appendix E).  The delay between obtaining the information sheet, expressing an 
interest in participation over the telephone and providing informed consent gave 
women the opportunity to think about entry to the study and discuss it with their 
partners prior to officially consenting.  
The researcher’s direct involvement in the consenting process helped to facilitate 
informed choice by allowing women the opportunity to ask any questions or to 
clarify any issues prior to signing their consent.  The information letter and the 
consent form outlined all the foreseeable risks and benefits of the research and 
contained the contact telephone numbers and email addresses of the researchers.  
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This gave women the opportunity to contact the researchers if they had any questions 
or concerns about the study.  It also specified in the consent form that women were 
able to withdraw their consent to participate at any time without ramifications to the 
care they received throughout their pregnancies.  
The information provided and the availability of the researchers for further questions 
ensured that the participants were able to acquire all the information they required to 
make an informed choice about involvement in the study. 
3.5.4 Confidentiality 
In order to protect the privacy of the participants, all the data collected was de-
identified at the time of collection.  The medical record numbers of each participant 
were documented with the data in order to allow for verification of any missing or 
ambiguous information upon completion of the trial.  Once the study was completed, 
all identifiable information, including medical record numbers, was deleted.   
The researcher was the only staff member at the study site with access to the raw 
data.  For the duration of the data collection phase, the information was stored in a 
locked cabinet at the research site.  Once data collection was completed, the raw data 
were transferred to a locked cabinet in the School of Nursing, Midwifery and 
Indigenous Health at the University of Wollongong.  The de-identified data were 
entered in the SPSS database by the researcher to allow for data analysis.  The data 
were saved and stored on a password-protected laptop computer.  The de-identified 
state of the data has been preserved at any time when the data has been presented in 
poster, written or oral format.   
All of these actions have ensured the safeguarding of participants’ privacy with 
respect to their involvement in the study.   
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3.5.5 Ethics summary 
As has been demonstrated above, all attempts were made to ensure the women and 
the unborn infants participating in the study were protected physically, 
psychologically and emotionally for the duration of the research.  This can be seen 
through the attention given not only to physical safety considerations but also to the 
rights of women to make a free, uncoerced, informed choice and to have their 
information remain private and confidential.  In summary, the attention paid to all 
these different aspects demonstrate that this study was performed in an ethical 
manner.   
3.6 Conclusion 
In order to determine the appropriateness of this study design to address whether the 
use of oral probiotics in pregnancy can impact vaginal GBS colonisation rates, a pilot 
RCT was performed.  This chapter has described the justification for the research 
design used in this study.  It has achieved this, firstly, by describing the 
methodological frameworks of a pilot RCT and a pragmatic trial, which were the 
underlying foundations of the study. Secondly, it has detailed the design by 
describing the study site, the study population, the recruitment strategy, the sample 
size and randomisation process, the intervention, the observations and the data 
analysis utilised in the study.  Lastly, it explained the ethical concerns arising from 
the study and the means by which the design addressed these concerns.    
The following chapter describes the findings that were generated through the 
research design detailed here. 
4. Findings 




This chapter presents the statistical findings that were generated by the study.  The 
first group of findings has been organised into a comparison of the antenatal 
demographics, a comparison of the final vaginal swab results and a comparison of 
the final vaginal swab results of a subgroup of the participants.  The second group of 
the findings presents comparisons of the variables pertaining to safety considerations 
within the study.  These variables include antenatal, immediately postnatal and six 
months postnatal safety considerations.  These are presented in order to determine 
the absence of adverse events associated with the intervention. 
Between April 2011 and July 2011, 34 GBS-positive pregnant women experiencing 
uncomplicated pregnancies were recruited into this study.  All the participants were 
in the late stages of their pregnancies at the time of recruitment.  The average mean 
gestation was 35 weeks and 5 days at the time when the first vaginal swab was 
collected. A pregnancy is considered to be at term at 37 weeks.  Due to the 
uncontrollable nature of labour and birth and the late stages of the participants’ 
pregnancies at the time of recruitment, a high attrition rate was anticipated.  A three-
month recruitment phase was performed with an anticipated minimum of 
30 participants.  In total, 34 women were recruited to participate in the study during 
this time frame. 
Of these 34 participants, 21 women were randomly allocated to the intervention 
group and 13 to the control group (for a complete explanation of the uneven 
participant allocation, please refer to p 25-26).  Of the 21 women in the intervention 
group, seven women were able to complete the entire 21 days of daily oral 
probiotics.  This was mainly due to participants birthing prior to completion of the 
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21-day intervention.  Seventeen women were successful in consuming at least 
14 days of oral probiotics. Two participants did not collect their second lower 
vaginal swab.  This occurred due to the precipitous nature of their individual births.  
Both of these women were allocated to the intervention group. 
A research study conducted by Morelli et al. (2004) found that Lactobacilli colonised 
the vagina after two weeks of a daily oral dose of GR-1 and RC-14 in a dose of 
>10
8 
culture-forming units.  For the purpose of the data analysis, and based on this 
research, the participants were further limited to a subgroup which included any 
women who had completed 14 days or more of probiotics.  This further reduced the 
participants to 17 women in the intervention group and 13 women in the control 
group.  Of the 17 woman in the intervention group, one woman did not complete the 
final lower vaginal swab due to the precipitous nature of her birth.  This further 
reduced the available final swab results in the subgroup to 16 in the intervention and 
13 in the control groups. 
A follow-up telephone survey of the participants was performed when their infants 
were approximately six months old.  The purpose of this survey was to collect further 
data to ensure the absence of adverse events with the intervention. All 34 women 
participated in this survey.  No participants were lost to follow-up.   
The following sections present the findings of this research project.  It is important to 
frame these findings within the context of its original design.  This project was set 
out to be a pilot. The aim was to ascertain the appropriateness of the design to guide 
the development of future research projects.  As such, the sample size was small and 
lacks power.  This increases the potential for Type 1 or 2 errors in the statistical 
results (Borbasi & Jackson, 2008).  Therefore, while the findings from this study are 
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intended to guide future research, assertions made on the basis of these findings 
alone should be considered carefully.   
The small sample size made tests of normality for the continuous data in the analysis 
unreliable.  In order to verify normal distribution and justify the use of the 
independent t-test on the continuous data in this analysis, the Mann-Whitney test was 
applied.  All of the Mann-Whitney tests applied to the continuous variables in this 
study had results which were non-significant, as were the results of the independent 
t-tests when applied to the same variables.  The Mann-Whitney test is a non-
parametric test.  The results of the Mann-Whitney tests support the results of the t-
tests in the findings (Batterham, personal communication 2015; Newton & 
Rudestam, 2013). 
The findings of the study have been classified into antenatal demographics, final 
lower vaginal swab results, subgroup analysis of final lower vaginal swab results, 
safety considerations and the six-month follow-up telephone survey.  
4.2 Antenatal demographics 
Upon entry to the study, antenatal demographic information was collected from each 
participant.  This information included age, ethnicity, BMI, parity and previous 
history of GBS.  Null parity refers to a woman who is currently experiencing her first 
pregnancy, which she has carried past the age of viability (Wong & Perry, 1998). 
Due to the small sample size, information collected on ethnicity could not accurately 
be statistically analysed. 
In order to compare the demographic variables between the probiotic and standard 
care groups, independent sample t-tests and Fisher’s exact tests were used.  Using the 
independent sample t-test, it was shown that the participants in the probiotics and 
standard care groups did not differ significantly with respect to age (Probiotic: 
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M=32, SD=4; Standard: M=30, SD=4.3, t(df)=1.7, p=0.1) and body mass index 
(BMI) (Probiotic: M=23.4, SD=3.8; Standard: M=23.7, SD=4.3, t(df)=-0.2, p=0.8).  
When a Fisher’s exact test was applied to the variables ‘Nulliparous’ and ‘Previous 
history of GBS’, the results were also found to be non-significant (p=0.5 and 0.6 
respectively, FET).  This indicates that both the probiotics and standard care groups 
in this specific group of participants have a degree of homogeneity with respect to 
age, BMI, null parity and history of GBS.  Therefore, these results aid to increase the 
confidence that these factors, with potential confounding effects, should not 
influence the findings of the study.  Since the two groups are similar in these areas 
prior to the intervention, it justifies the comparison of these two groups following the 
intervention.   
4.3 Final lower vaginal swab results 
The aim of this study was to complete a pilot project to ascertain if the research 
design was appropriate to determine whether a daily oral dose of probiotics can 
reduce the rate of vaginal group B streptococcal (GBS) colonisation in pregnancy.  
To determine whether a relationship existed in this study between oral probiotic 
consumption and GBS-negative vaginal swab results, a Fisher’s exact test was 
applied to the data. 
4.3.1 Timing between the first and second vaginal swabs 
In order to ensure consistency between the two groups and control for possible 
confounding factors, the time between collecting the first vaginal swab and second 
vaginal swab for the probiotic and standard care groups was compared.  If one group 
had a significantly longer time period between performing their first and second 
vaginal swabs, this would have the potential to impact the number of swabs 
spontaneously reverting to a negative result independent of the intervention. This 
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comparison was performed using an independent sample t-test.  In this analysis the 
mean number of days between collection of the first and second vaginal swab for 
both the probiotic and control groups was 25 days, producing a non-significant result 
(Probiotic: SD=5.3; Standard: SD=9.7, t(df)=0.3; p=0.8).  This indicates that the 
number of days between collecting the two swabs was similar for both the probiotic 
and standard care groups.  In this analysis, it was assumed that the two participants 
who missed collecting their second swabs due to precipitate labours, if it had been 
possible, would have collected their swabs on the same day that they gave birth.   
4.3.2 Comparison of final lower vaginal swab results 
It has been verified that similarity exists between the intervention and control groups 
in the aforementioned variables.  Therefore, since it has been determined that a 
degree of homogeneity exists between the probiotic and standard care groups in this 
specific sample, the comparison of the final lower vaginal swab results between the 
two groups is justified.  In the control group, involving 13 women, it was found that 
three women were GBS negative when the final swab was collected.  In the 
probiotics group, involving 21 women, two of the participants had no final swab 
collected.  Of the remaining 19 women in the probiotics group, four were determined 
to be GBS negative, as indicated by their final lower vaginal swab.  Using the 
Fisher’s exact test, it was discovered that the group of women consuming an oral 
daily dose of probiotics did not have a significant decrease in GBS in their vaginas, 
as indicated by their final swab result when compared with the control (p=0.7, FET).  
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Table 1: Comparison of final swab results by group allocation 
 
Intervention status Final Lower Vaginal Swab 
Result (N) 
 Negative Positive Total 
Probiotics 4 15 21 
Standard 3 10 13 
Total 7 25 34 
 
Figure 1: Comparison of final swab results by group allocation 
 
4.4 Subgroup analysis of final vaginal swab results 
4.4.1 Subgroup analysis of GBS results 
The number of days that women in the intervention group took the probiotics varied 
from six days to 21 days, with an average mean of 17 days.  Only eight of these 
participants completed 19 or more days, with the missing days being attributed to 
forgotten doses.  The reason why participants completed fewer than 19 days of 
probiotics was that they birthed prior to completion of the course of probiotics. The 
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foundation for the decision to perform a three-week intervention was the finding that 
the probiotics RC-14/GR-1 in the dose of >10
8 
culture-forming units can colonise the 
vagina after 14 days of oral consumption (Morelli et al., 2004).  The premise of the 
current study was that women with higher colonisation of Lactobacilli in their 
vaginas have a greater probability of being GBS negative.  Therefore, if previous 
research has shown that these probiotics can colonise the vagina after two weeks of 
oral use, then, in the current study, it would not be expected for the women’s GBS 
statuses to be impacted until at least 14 days of probiotic use.  In light of this, a 
further subgroup analysis of the final swab results was performed including only the 
women in the intervention group who had completed at least 14 days of oral 
probiotics.  
The subgroup limited the intervention group to 17 women and the control group to 
13 women.  In the intervention subgroup, one woman did not have a final lower 
vaginal swab collected due to precipitous labour, further reducing the intervention 
group to 16 women.  When the Fisher’s exact test was applied to this subgroup, the 
results remained above significance (p=1.0, FET), indicating no difference in the rate 
of GBS-negative final swabs between the intervention and control when including 
only the women in the intervention who had completed at least 14 days of oral 
probiotics.  These results are summarised in Table 2 and Figure 2. 
Table 2: Comparison of the subgroup analysis of final swab results from the 
intervention and control groups 
    
Intervention status Final Lower Vaginal Swab 
Result (N) 
 Negative Positive Total 
Probiotics 3 13 16 
Standard 3 10 13 
Total 6 23 29 
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Figure 2: Comparison of subgroup analysis of final swab results by group 
allocation 
 
4.4.2 Subgroup analysis comparing the presence of commensals 
A secondary, unexpected finding in this study was that the lower vaginal swab 
results indicated the presence of commensals in a number of women’s vaginas.  At 
the study site, the pathology department routinely reported on both the presence of 
GBS and the presence of commensals. Commensals are normal vaginal flora 
(Barrons & Tassone, 2008; Lagenaur et al., 2011b; Rose et al., 2012).  In this study, 
the presence of commensals was reported in final vaginal swabs among the women 
who took a daily dose of probiotics for at least 14 days: five women in the probiotics 
group had commensals and no women in the standard care group had commensals.  
Of these five women, none had had the presence of commensals reported in their 
vaginas at the initial 36-week swab.  When the Fisher’s exact test was applied to 
determine the presence of an association between consuming oral probiotics and the 
presence of commensals, a significant result  was obtained (p=0.048, FET).  This 
result indicates that the women in this study consuming a daily oral dose of 
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probiotics for 14 days or more had a significantly increased probability of having 
commensals in their vaginas in comparison to the women allocated to the standard 
care group.  These findings have been summarised in Table 3 and Figure 3. 
Table 3: Comparison of the presence of commensals by group allocation 
  
Intervention status Presence of Commensals (N) 
 No Yes Total 
Probiotics 11 5 16 
Standard 13 0 13 
Total 24 5 29 
 
Figure 3: Comparison of the presence of commensals by group allocation 
 
4.5 Safety considerations 
One of the major concerns surrounding probiotic use in pregnancy is the assurance of 
safety for both the mother and the infant.  A more detailed discussion of this topic 
can be found in the literature review chapter.  This section presents the findings of 
the study pertinent to the safety of probiotic use in pregnancy.  The safety indicators 
for this section and for the questions in the six-month follow-up telephone survey 
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have been adapted from two systematic reviews conducted on the safety of probiotic 
use in pregnancy (Allen et al., 2010; Dugoua et al., 2009).  Furthermore, the 
indicators for allergy-related concerns in the six-month follow-up telephone survey 
were adapted from a systematic review of the impact of probiotic use in pregnancy 
on eczema (Kalliomaki et al., 2001). 
4.5.1 Antenatal concerns 
Data were collected on each participant regarding the emergence of complications in 
the pregnancy after entry to the study.  Two women were found to develop 
complications, one with pregnancy-induced hypertension and one with pruritic 
urticarial papules and plaques of pregnancy (PUPPS).  Both of these women had 
been allocated to the standard care group. 
4.5.2 Side-effects 
After the second vaginal swab was collected from each participant, information was 
collected documenting the self-reported side-effects women in the intervention group 
experienced from the probiotics.  Two out of the 21 women in the probiotics group 
stated having side-effects.  One woman reported that she experienced an itchy throat.  
She was uncertain whether this was due to the probiotics.  One other woman reported 
that the probiotics assisted her with her constipation.  None of the remaining 
19 women reported any side-effects from the probiotic usage. 
4.5.3 Birth outcomes 
In order to further explore the area of probiotic safety in pregnancy, data pertaining 
to a number of birth outcomes was collected.  This included birth weight, gestation at 
the time of birth, and mode of birth/delivery. 
4. Findings 
   46 
 
4.5.4 Birth weight and gestation at the time of birth 
The mean birth weight for the 21 infants born to the women in the intervention group 
was 3,545 grams.  The mean birth weight for the 13 infants born to women in the 
standard care group was 3,542 grams.  An independent sample t-test was applied to 
the birth weights to determine if there was a significant difference between the two 
groups with regard to birth weight.  No significant difference was found (Probiotics: 
SD=379; Standard: SD=370, t(df)=0.02, p=0.98). 
The mean pregnancy gestation at the time of birth was also compared between the 
two groups.  This information was to aid in determining whether probiotics could 
impact the time at which a woman may go into labour.  It was calculated that the 
mean gestation at the time of birth for the women in the probiotics group was 
39.7 weeks and in the standard care group was 39.9 weeks.  The results of the 
independent sample t-test verified that there was no significant difference between 
the two groups (Probiotics: SD=1.2; Standard: SD=1.0, t(df)=-0.7, p=0.5). 
4.5.5 Mode of birth 
The final safety indicator investigated with regard to birth outcomes in this study was 
mode of birth.  The four identified modes of birth were normal vaginal birth, 
instrumental birth, elective lower segment caesarean section (LSCS) or emergency 
LSCS.  An instrumental birth indicates the need for a vacuum or forceps delivery.  
An elective LSCS refers to a caesarean section that has been planned in advance.  An 
emergency LSCS refers to a caesarean section that has been unplanned and has 
occurred because of an unforeseen event, such as ‘foetal distress’ or ‘failure to 
progress’. 
Of the 21 women in the probiotics group, 19 experienced a normal vaginal birth, one 
underwent an instrumental birth and one underwent an elective caesarean.  Of the 
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13 women in the standard care group, six women experienced a normal vaginal birth, 
two underwent an instrumental birth, two underwent an elective caesarean and three 
underwent an emergency caesarean.  A summary of these findings can be found in 
Table 4 and Figure 4.  





Mode of Delivery (N) 









Probiotics 19 1 1 0 21 
Standard 6 2 2 3 13 
Total 25 3 3 3 34 
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In order to compare these groups further, instrumental birth and emergency LSCS 
were grouped together into assisted delivery.  Elective LSCSs were not included in 
this group, as they were planned in advance and were, therefore, births that did not 
require an emergency intervention. This categorisation further reduced the data to 
one woman in the probiotics group requiring an assisted delivery and five women in 
the standard care group requiring an assisted delivery.  When a Fisher’s exact test 
was applied to this data, the women in the standard care group were shown to have 
significantly more assisted deliveries than the women in the probiotics group 
(p=0.02, FET).  These results have been summarised in Table 5. 
Table 5: Comparison of assisted delivery rates by group allocation 
  
Intervention status Assisted Delivery (N) 
 No Yes Total 
Probiotics 20 1 21 
Standard 8 5 13 
Total 28 6 34 
 
 
These findings imply that probiotics may have a protective property when consumed 
in later pregnancy.  One possible confounding variable that may impact these 
findings is the fact that women who are undergoing their first labour and birth 
experience (nulliparous) have a greater probability of experiencing an assisted 
delivery (Baskett et al., 2008).  If there were more nulliparous women in the standard 
care group as compared to the probiotics group, this could skew the data.  In 
response to this, the data were further limited to the 18 nulliparous women 
participating in the study.  Within this category, one out of 10 nulliparous women in 
the probiotics group underwent an assisted delivery and five out of eight nulliparous 
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women in the standard care group underwent an assisted delivery.  A Fisher’s exact 
test indicated that the significance remained despite limiting the data to nulliparous 
women (p=0.04, FET).  A summary of the data can be found in Table 6.  Due to the 
small sample size, it would be unreasonable to conclude that probiotics have a 
protective effect on birth outcomes, but these results do support the evidence that 
probiotic use in later pregnancy does not produce negative birth outcomes. 
Table 6: Comparison of assisted delivery rates in nullips by group allocation 
  
Intervention status Assisted Delivery (N) 
 No Yes Total 
Probiotics 9 1 10 
Standard 3 5 8 
Total 12 6 18 
 
4.5.6 Pre-labour spontaneous rupture of membranes 
One unexpected outcome was the number of women who experienced a pre-labour 
spontaneous rupture of membranes (SROM) in the study.  Four out of the 21 women 
in the probiotics group and one out of the 13 women in the standard care group had a 
pre-labour SROM. When analysed further with a Fisher’s exact test, a comparison of 
the SROM rates for the two groups was not statistically significant (p=0.6, FET).  
However, this may be an area to be alert to for future studies.  A summary of these 
results can be found in Table 7. 
Table 7: Comparison of pre-labour SROM rates by group allocation 
  
Intervention status Prelabour SROM 
 No Yes Total 
Probiotics 17 4 21 
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Standard 12 1 13 
Total 29 5 34 
 
4.6 Follow-up telephone survey 
A follow-up telephone survey was performed approximately six months after birth 
for all the women involved in the study.  The participation rate for the telephone 
survey was 100 per cent: all 34 participants were contacted and interviewed.  The 
purpose of the survey was to collect further data on the safety of probiotic use in later 
pregnancy and to determine whether the probiotic use had had any impact on the 
development of eczema, asthma or allergic rhinitis in the infants of the participants. 
The survey collected some demographic information to aid in controlling for 
confounding variables.  This information included the method and duration of infant 
feeding, the presence of smokers or pets in the home, the infant’s exposure to 
childcare, and the family history of allergies, eczema and asthma.  The survey then 
collected information about the infant regarding the number of doctors’ visits, 
presentations to the emergency department and hospitalisations.  It also collected 
information on whether the infant had had any concerns at birth, such as neonatal 
GBS infection, and whether the infant had shown any signs of eczema, allergies, 
asthma or allergic rhinitis.  Finally, the mother was asked to rate the health of her 
infant as ‘very healthy’, ‘occasionally unwell’ or ‘nearly always unwell’, and given 
the opportunity to comment further on the health of her infant.  Refer to Appendix G 
to review a copy of the survey. 
4.6.1 Demographic information 
The demographic information collected by the survey was: method of infant feeding, 
duration of exclusive breastfeeding, the presence of smokers in the house, the 
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presence of pets in the house, the infant’s attendance at childcare, and the family 
history of allergies, asthma or eczema. These are all variables that may contribute to 
the overall health of the infant.  These variables were compared statistically between 
the probiotic and standard care groups of participants.  An independent sample t-test 
was applied to the variable length of exclusive breastfeeding (Probiotic: M=4.2 
months, SD=2.2; Standard: M=3.5 months, SD=2.6, t(df)=0.9, p=0.4) and a Fisher’s 
exact test was applied to the variables: presence of smokers (p=1.0, FET), presence 
of pets (p=0.7, FET), attendance at childcare (p=1.0, FET) and family history (p=1.0, 
FET).  Based on these statistical analyses, no significant differences were found for 
any of the variables.   
The final demographic variable that was considered was the method of infant feeding 
at six months of age.  Of the 21 women in the probiotics group, 11 of their infants 
were breastfed, nine infants were formula fed and one infant received a combination 
of breast and formula feeds.  Of the 13 women in the standard care group, seven of 
their infants were breastfed, five infants were formula fed and one infant received a 
combination of breast and formula feeds.  A Fisher’s exact test cannot be applied to 
an analysis with three variables.  A chi square test was not appropriate due to the 
small sample size.  Therefore, no tests of significance were applied to this data.  A 
summary of these results can be found in Table 8.   
Table 8: Comparison of infant feeding methods at six months between the 
intervention and control groups 
 
Intervention status  Method of Feeding at 6 Months (N) 
 Breast feeding Formula Combination Total 
Probiotics 11 9 1 21 
Standard 7 5 1 13 
Total 18 14 2 34 
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4.6.2 Infant well-being at six months of age 
The remaining sections of the survey collected data relating to the well-being of the 
infant.  The indicators used to ascertain this were: health concerns at birth, number of 
visits to the doctor, number of visits to hospital emergency departments, number of 
hospitalisations, use of medications, and presence of asthma, allergies, rhinitis or 
eczema.  The participants were also asked to rate their infants’ health as ‘very 
healthy’, ‘occasionally unwell’ or ‘nearly always unwell’.  Finally, the participants 
were given the opportunity to comment further on health concerns relating to their 
infants. 
4.6.3 Concerns at birth 
Among the participants, two women in the probiotics group and one woman in the 
standard care group reported that their infants had concerns at birth.  The two 
concerns noted in the probiotics group were low Apgar scores and clicky hips.  The 
one concern noted in the standard care group was transient tachypnoea of the 
newborn.  None of the participants reported neonatal GBS infections in their infants. 
All of these concerns resolved after the immediate postpartum period.  The Fisher’s 
exact test indicated that there was no association between group allocation and 
concerns at birth (p=1.0, FET).   
4.6.4 Encounters with the medical system 
The second group of indicators collected information on the number of encounters 
the infant had had with the medical system in the first six months of life.  These 
encounters were broken down into visits to the doctor, visits to emergency 
departments and hospitalisations.  The routine vaccination visits to the GP were not 
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included in the tally of doctors’ visits.  The mean number of visits to the doctor for 
the probiotics group was 1.5 visits.  The mean number of visits to the doctor for the 
standard care group was 1.9 visits.  The maximum number of visits for one infant in 
the probiotics group was 10 visits.  These visits were for an infant with reflux who 
had also contracted rubella in the first six months of life.  The maximum number of 
visits to the doctor in the standard care group was 12 visits.  These visits were for an 
infant who had developed a haemangioma post discharge from the hospital.  He had 
required fortnightly visits to a specialist at the Sydney Children’s Hospital.  By six 
months of age, these visits had been reduced to every second month.  An 
independent sample t-test indicated no difference in means between the two groups 
with respect to their number of doctors’ visits (Probiotics: SD=2.8; Standard: 
SD=3.2; t(df)=-0.3, p=0.8).  
The mean number of visits to the emergency department for the probiotics group was 
0.2.  The mean number of visits to the emergency department for the standard care 
group was 0.2.  The probiotics group had four presentations to emergency; the 
standard care group had two presentations.  In the probiotic group, two of the 
presentations were for the same infant who had begun projectile vomiting when 
commenced on formula.  This infant was later diagnosed with cow’s milk 
intolerance.  One presentation was due to constipation when commenced on formula.  
The final presentation was due to pyloric stenosis.  This infant was hospitalised and 
required surgery at Sydney Children’s Hospital.  The two presentations in the 
standard care group were for a virus and bronchiolitis.  The infant with bronchiolitis 
was admitted and treated in hospital for the infection.  An independent sample t-test 
indicated that no significant difference existed between the mean number of 
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presentations to the emergency department between the probiotics and standard care 
group (Probiotics: SD=0.5; Standard=0.4, t(df)=0.2, p=0.8).  
One infant in the probiotics group and two infants in the standard care group required 
hospitalisation in their first six months of life.  The infant in the probiotics group was 
admitted to hospital for pyloric stenosis.  The two infants in the standard care group 
were admitted to hospital for bronchiolitis and haemangioma. A Fisher’s exact test 
indicates that there was no association between incidence of hospitalisation and 
group allocation (p=0.5, FET).  
In this study, no significant association existed between the group allocation and 
encounters with the medical system in the first six months of life.  This further 
supports the absence of adverse events in this study with the use of probiotics in later 
pregnancy. 
4.6.5 Medications 
The incidence of infant medication use was also an indicator for infant well-being.  
The most frequently reported medication taken by the infants in this study was 
Losec.  This is an anti-reflux medication.  In the probiotics group three infants were 
taking Losec and in the standard care group two infants were taking Losec.  The only 
other medication reportedly used was Propranolol, a beta blocker, which was being 
used to treat one infant with haemangioma. A Fisher’s exact test statistic showed no 
association between group allocation and incidence of medication use (p=0.7, FET).   
4.6.6 Allergy-related health concerns 
Information was also collected on the incidence of allergy-related health concerns 
that had developed in the infants.  The indicators used to determine these health 
concerns were the occurrence of asthma, eczema, allergic rhinitis or allergies in the 
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infants.  Many research studies have indicated a trend in a reduction in allergy-
related illness in infants whose mothers used probiotics in later pregnancy 
(Kalliomaki et al., 2001).  This information aimed to discover whether any such 
trend could be seen in this research project. 
Only one woman reported having an infant with possible asthma.  This woman was 
in the probiotics group.  Her infant had had some incidences of wheezing and was 
currently under investigation with a paediatrician for asthma.  One woman also 
reported having an infant with rhinitis.  This woman was in the probiotics group.  
She described her infant as having a continuously runny nose.  Both of her other 
children and her husband were asthma sufferers and they also had other allergy-
related health concerns.  Only one woman also reported having a child with allergies.  
This woman was in the probiotics group.  Her infant had been diagnosed with cow’s 
milk intolerance after commencing on formula.  These frequencies were too low to 
permit reliable statistical analysis.  
The final allergy-related concern that was explored was the incidence of eczema.  
Three women reported that their infants experienced mild skin rashes or irritations 
but were uncertain whether this was eczema.  Two of these women were in the 
probiotics group and one woman was in the standard care group.  One woman in the 
probiotics group and three women in the standard care group reported eczema in 
their infants.  Of this total of seven women, all but one quantified their infant’s skin 
concerns as mild or slight.  When all the uncertain answers were assumed to be yes 
and the Fisher’s exact test was applied to this variable, no significant association was 
shown to exist between incidence of eczema and group allocation (p=0.4, FET).  For 
a summary of these findings, see Table 9. 
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Table 9: Summary of incidence of eczema by group allocation 
 
Intervention status Incidence of Eczema (N) 
 No Yes Total 
Probiotics 18 3 21 
Standard 9 4 13 
Total 27 7 34 
 
4.6.7 Overall health 
The final indicator used to assist in determining the overall well-being of the infants 
of the study participants at six months of age was a scale which asked women to 
describe their baby’s health as: ‘very healthy’, ‘occasionally unwell’ or ‘nearly 
always unwell’.  Only one woman described her infant as ‘occasionally unwell’; all 
the other participants described their infants as ‘very healthy’.  This woman was in 
the standard care group.  Her infant had been diagnosed with haemangioma at three 
weeks of age and at six months required twice daily medication and frequent follow-
up with doctors.  These results were too low to permit for reliable statistical analysis. 
As a conclusion to the telephone survey, women were asked whether there were any 
other health concerns that they would like to mention regarding their baby.  Three 
participants offered further responses to this question.  One woman in the probiotics 
group reported that her infant was seeing a physiotherapist once a month because the 
infant preferred to turn her head to one side.  Another woman in the probiotics group 
reported that her infant had had one episode of diarrhoea in the past six months.  
Finally, one woman from the standard care group reported that her infant was a poor 
sleeper.   
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4.6.8 Conclusion to six-month follow-up telephone survey 
The study lost no participants to follow-up.  All 34 participants were contactable for 
the six-month follow-up telephone survey.  The data provided by the six-month 
follow-up study found that no significant differences existed between the 
confounding variables in the probiotics and the standard care groups.  The study also 
found no differences between the two groups relating to the overall health of the 
infants of the study participants at six months of age.  These findings further support 
the lack of adverse events with probiotic use in later pregnancy in healthy women 
experiencing uncomplicated pregnancies. 
4.7 Conclusion 
In summary, this study found that no differences existed between the probiotics and 
standard care groups with regard to demographic information collected both at the 
time of recruitment and at the time of the six-month follow-up survey.   
Further, no significant difference was found between the two groups with regard to 
most of the safety indicators investigated in the study.  The only difference that was 
discovered was in mode of delivery, where women in the standard care group were 
found to have a greater incidence of assisted deliveries. This difference remained 
even when the data were limited to nulliparous participants.  These findings further 
support the lack of adverse events with probiotic use in later pregnancy in healthy 
women experiencing uncomplicated pregnancies. 
The aim of this study was to ascertain the appropriateness of the research design to 
determine whether a daily oral dose of probiotics could impact a pregnant woman’s 
GBS status, as indicated by a lower vaginal swab.  The women in the probiotics 
group did not show a reduction in the incidence of GBS in their vaginas in 
comparison to the standard care group.  A subgroup analysis, including only women 
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in the intervention group who had taken at least 14 days of probiotics, also found no 
reduction in the incidence of vaginal GBS in comparison to the standard care group.  
But an unexpected, secondary finding did show that the subgroup had a significant 
increase in the presence of commensals in the vaginas of the women in the probiotics 
group.  This finding has ramifications for future studies, as will be explored further 
in the discussions chapter. 
5. Discussion 




The following chapter discusses the multiple findings that have been generated by 
this research project.  The hypothesis of the study asked the question: if 
Lactobacillus colonisation rates can be increased in pregnant women’s vaginas, 
could this result in a decrease in group B streptococcal (GBS) colonisation rates? 
One potential means of manipulating Lactobacillus concentrations in order to 
attempt to impact GBS colonisation rates is through the use of probiotics.  The aim 
of this study was to complete a pilot project to ascertain if the research design of this 
study was appropriate to determine if a daily oral dose of probiotics can reduce the 
rate of vaginal group B streptococcal (GBS) colonisation in pregnancy. 
This research project did not discover any significant difference in vaginal GBS 
colonisation rates in women who had consumed daily oral doses of probiotics as 
compared to women who had not.  This chapter discusses the possible explanations 
for the lack of positive results in this study.  It also presents the limitations of the 
study.  Finally, it presents the strengths of the study with an emphasis on the 
information that has been generated to aid in the development of future research 
designs. 
5.2 Possible reasons for the lack of results relating to probiotic use and 
vaginal GBS 
The aim of this study was to complete a pilot project to ascertain if the research 
design was appropriate to determine whether a daily oral dose of probiotics can 
reduce the rate of vaginal group B streptococcal (GBS) colonisation in pregnancy.  In 
this study, only seven of the 21 participants in the intervention group succeeded in 
completing the full 21 days of probiotics.  In order to manage this problem, a 
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subgroup analysis was performed including participants in the intervention group 
who had completed 14 days or more of probiotics.  This decision was based on 
research which has shown that Lactobacilli rhamnosus GR-1 (GR-1) and 
fermentum/reuteri RC-14 (RC-14) can colonise the vagina after 14 days of oral 
consumption (Morelli et al., 2004; Reid et al., 2001).  The subgroup analysis found 
no significant difference in the rate of vaginal GBS post intervention between the 
control and probiotic groups. 
As this was a pilot study, one of the purposes of the study was to analyse the results 
in the light of the study design in order determine areas that require improvement for 
future designs.  There are numerous potential explanations for the lack of positive 
findings in this study. These explanations include: inadequate length of intervention, 
incorrect strain of probiotic, inadequate dosage of probiotic, and possible ineffective 
treatment.  The following sections address the possible explanations for the lack of 
positive results in further detail, with the intention of aiding the design of future 
research projects. 
5.2.1 Inadequate length of intervention 
The initial expected length of the intervention period was three weeks of probiotic 
consumption.  As stated earlier, due to the late gestation of 36 weeks at which the 
participants were recruited and due to the unexpected nature of labour and birth, only 
seven of the 21 participants allocated to the intervention group were successful in 
completing the entire three-week intervention.  In response, a subgroup analysis was 
completed including the participants in the intervention group who had completed 
14 or more days of probiotics.  A subgroup analysis examines the effects of the study 
on different subgroups within the study after analysing the main hypothesis of the 
study (Peat, 2001). This limited the participants in the intervention group to 17.  One 
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of these participants was unable to collect a final vaginal swab due to the precipitous 
nature of her labour.  This further limited the subgroup analysis to 16 participants in 
the intervention group.   
The late gestation at recruitment—and the resulting large number of participants 
unable to complete the intervention—is an obvious shortfall of the study design.  It 
was decided to recruit women in the final weeks of their pregnancies in order to 
utilise the vaginal GBS screening that was already being routinely performed at the 
study site at 36 weeks gestation.  This choice was purely one of economic 
rationalisation.  This study has made it obvious that this gestation was too late to 
commence the intervention. 
Previous research which procured positive results with respect to bacterial vaginosis 
with the use of the same probiotic strains as the current study had an intervention 
period of between 28 and 60 days (Krauss-Silva et al., 2011; Reid et al., 2003; Reid 
et al., 2004; Anukam et al., 2006b; Martinez et al., 2009).  This further emphasises 
that future research will need to intervene at an earlier gestation and aim for at least a 
four-week intervention period. 
In addition, a secondary, unexpected finding of the study was that women who had 
taken daily probiotics for at least 14 days were found to have significantly more 
commensals in their vaginas in the probiotics group versus the control group.  
Commensals are normal vaginal flora, such as Lactobacilli (Barrons & Tassone, 
2008; Lagenaur et al., 2011b; Rose et al., 2012).  This finding suggests that possibly 
the probiotics had begun colonising the vaginas of the women in the intervention 
group with Lactobacilli but the colonisation was not significant enough to impact on 
the colonisation of GBS.  As such, this finding sways the reason for the lack of 
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positive results towards a problem with the length of the intervention, with the 
dosage of the intervention or with both. 
5.2.2 Inadequate probiotic dosage 
Another possible explanation why the probiotics did not impact on the vaginal GBS 
colonisation rates of the participants in this study is that the probiotic dosage may 
have been too low. The women randomly assigned to the intervention group 
consumed a daily oral dose of the probiotics Lactobacillus rhamnosus GR-1 (GR-1) 
and Lactobacillus fermentum/reuteri RC-14 (RC-14) in a dose of 10
9
 viable strains.  
Reid et al. (2003, 2004) report that this dosage positively impacted the vaginal micro 
flora of their participants when given daily for 60 days.  Alternatively, Anukam et al. 
(2006b) and Martinez et al. (2009) both found GR-1 and RC-14 to positively impact 
the cure rate for bacterial vaginosis post-antibiotic treatment when given in a dosage 
of 10
9 
viable strains twice daily for 30 days in its non-pregnant participants.  These 
research projects would support the consideration of a twice daily dose, instead of a 
once daily dose, of probiotics if using a 30-day intervention period for future studies.   
The one challenge that may arise from increasing the probiotic dosage from once 
daily to twice daily in future studies would hedge around safety issues.  In order for 
ethics approval to be obtained, it would be necessary to adequately prove to the 
ethics board that this increased dosage would not cause harm to the pregnant woman 
or her unborn child. The ethics process for this study took one year due to the 
justifiably weighty concern placed on the safety of women and their unborn infants 
by the ethics board when exploring emerging treatments in pregnancy.  One 
stipulation placed on this study by the ethics board prior to approval was that a 
follow-up survey be completed six months after each participant’s birth in order to 
further explore the issue of safety.  Based on this experience, it can be anticipated 
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that an increase in dosage would also come under high levels of scrutiny by the 
ethics board. 
5.2.3 Incorrect strain of probiotic 
Another potential explanation for the lack of a significant change in vaginal 
colonisation rates in the participants who consumed daily oral probiotics is the 
possibility the study used the incorrect strain of probiotics (Lamont et al., 2011).  The 
probiotic strains Lactobacillus rhamnosus GR-1 and reuteri/fermentum RC-14 were 
chosen because they have been shown to survive passage through the gastro-
intestinal tract and to colonise the vagina after oral consumption (Morelli et al., 2004; 
Reid et al., 2001; Reid et al., 2003; Reid et al., 2004).  This feature of these strains 
made them a justifiable choice for use in this study.   
Recently, two separate studies have emerged which have performed in vitro 
experiments specifically investigating the impact of different strains of Lactobacillus 
on GBS (Bodaszewska-Lubas et al., 2012; Ruiz et al., 2012).  The study by Ruiz et 
al. (2012) found that the Lactobacillus strains rhamnosus L60 and fermentum/reuteri 
L23 have probiotic potential for the control of vaginal GBS colonisation.  The strains 
used by Ruiz et al. (2012) and the strains used in the present study are similar to the 
species level.  The strains used in the present study are currently manufactured and 
readily available within the Australian market.  All these factors continue to support 
the use of RC-14 and GR-1 in future studies.   
On the other hand, probiotics have been shown to have strain-specific health benefits 
(Martinez et al., 2009; Pham et al., 2008; World Health Organisation , 2002).  This 
makes room for the possibility that the probiotic strains used in this study, though 
they colonise the vagina, may not have the ability to impact on GBS colonisation. 
The second in vitro study by Bodaszewska-Lubas et al. (2012) found Lactobacillus 
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plantarum C11 to have the strongest antibacterial properties against GBS. In 
addition, Lamont et al. (2011), in their review on impacting genital tract flora using 
molecular based techniques, recommend that ‘future research should concentrate on 
the Lactobacilli that are prevalent in the vagina, rather than on species such as L. 
fermentum and L. rhamnosus’ (p. 538). These authors recommend focusing on the 
Lactobacillus strains L. crispatus, L. iners, L. jensenii and L. gasseri when 
conducting research to impact vaginal health.  The use of L. jensenii can further be 
supported by research done using monkeys (Lagenaur et al., 2011a&b). 
Since this is an emerging area of research, many new studies are being published 
each year investigating the impact of probiotics on the vaginal ecology of women.  
These studies are being completed using a variety of strains of Lactobacilli and using 
both oral and vaginal administration.  Studies continues to support the positive 
potential of probiotics to modulate the vaginal microbiota.  It will be interesting to 
discover which strain or combination of strains emerge as the best choice for vaginal 
health through future research (Ehrstrom et al., 2010; Marcone et al., 2010; 
Stojanovic et al., 2012; Vitali et al., 2012; Wang et al., 2010).  
In summary, if an increase in length of intervention time and an increase in probiotic 
dosage did not improve the results of this study, it would be justifiable to explore the 
impact of other strains of probiotics on vaginal GBS colonisation prior to rejecting 
the hypothesis. 
5.2.4 Ineffective treatment 
The final possibility for the lack of significant results pertaining to the use of oral 
probiotics to impact vaginal GBS colonisation rates is that probiotics may be an 
ineffective treatment.  Before arriving at this final conclusion, the other possible 
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explanations that have arisen from the study design need to be explored further with 
future research projects. 
5.2.5 Conclusion to possible reasons for the lack of positive results 
There is a very real possibility that the strains chosen for this study may not be the 
most effective probiotics for impacting vaginal GBS or that this may be an 
ineffective treatment for the control of vaginal GBS.  However, the research, at this 
stage, indicates that the most logical explanations for the lack of positive results are 
the length of intervention and the dosage.  Once these areas have been further 
investigated and no impact noted, a change of probiotic would then be justified.  
After all these avenues have been explored, it would be prudent to reject oral 
probiotics as a possible treatment for vaginal GBS.  
5.3 Limitations to the study design 
As stated earlier, this was a pilot project.  It was intended to be the preliminary 
testing to determine the viability of the study design’s ability to address the study 
hypothesis.  The proposed hypothesis was that probiotics will decrease vaginal GBS 
colonisation rates in pregnant women.  The fact that this study was a pilot project and 
that it was based on a pragmatic approach to research generates limitations regarding 
the results.  This section expands on these limitations. 
5.3.1 Sample size 
One of the limitations present in this study was the small sample size.  In total, 
34 women were recruited over a three-month period. Initially, a power calculation 
was performed to determine the sample size necessary for a large randomised 
controlled trial (RCT).  It was calculated that a sample size of 217 participants per 
arm of the study would be required to reach a 90 per cent significance rate.  A pilot 
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study, with a small sample size, was utilised to determine the feasibility of the study 
design and of the recruitment strategy prior to committing the time and resources to a 
large RCT.   
The small sample size in the study gives rise to the increased risk for Type 1 or 2 
errors in the statistical results.  A Type 1 error is when a true hypothesis is rejected 
and a Type 2 error is when a false hypothesis is accepted (Peat, 2001).  Therefore, 
despite the small sample size, the findings of this study can serve to guide future 
research.  The small sample size limits the generalisability of the results.  It also 
means that the magnitude of the results needs to be cautiously interpreted in the 
context of their original purpose.  This purpose was to serve as a guide for future 
study designs. 
5.3.2 Uneven distribution of random allocation to control and intervention 
groups 
Another complication that the small sample size contributed towards was the uneven 
distribution of the random allocation to the control and the intervention groups. A 
three-month data collection time frame was set, with an anticipated minimum 
number of 30 participants and an uncapped maximum number of participants to be 
recruited within this time frame. A simple randomisation strategy was utilised in the 
study (Kang et al., 2008). The randomisation process was computer generated by an 
online site.  One hundred possible participants were randomised into group 1 or 
group 2.  The participants allocated to group 2, the intervention group, were heavily 
weighted at the beginning of the randomised series.  Therefore, of the 34 women 
recruited, 21 were randomised to the intervention group and only 13 to the control 
group.  Though unplanned, this uneven distribution worked in well with the research 
because, when the results were limited to only the participants in the intervention 
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group who had completed 14 or more days of probiotics and who had completed the 
final vaginal swab, only 16 participants remained.  The subgroup analysis, therefore, 
ended up with 13 women in the control group and 16 women in the intervention 
group. 
In addition, despite the uneven distribution, when the two groups were statistically 
compared they were found to be similar in their antenatal demographics, length of 
time between first and second vaginal swabs, and gestation at birth.  Since the two 
groups were comparable in these areas, this minimised the concern about external 
confounding factors that may have impacted the final vaginal swab results (Peat, 
2001).  The comparison of the final vaginal swab results was therefore justified.  
Even though the uneven distribution did not appear to adversely impact the study, it 
did not produce ideal circumstances for data analysis.  Simple randomisation 
strategies have been noted to be problematic in trials with small sample sizes, as they 
can produce unequal numbers of participants between groups.  A block 
randomisation technique would have been more appropriate to control for equal 
distribution of participants between groups in this study (Kang et al., 2008).  
Alternatively, a larger sample size of greater than 100 participants would have 
eradicated the limitation produced by a simple randomisation method. 
5.3.3 Timing of intervention 
As discussed in detail in section 5.2.1, ‘Inadequate length of intervention’, the timing 
of the intervention was a glaringly obvious limitation of the study.  The late gestation 
at which the participants were recruited and at which the intervention was 
commenced resulted in only seven of the 21 participants in the intervention group 
completing the entire 21 days of probiotics.  This accounts for a 66 per cent attrition 
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rate.  For future research studies, it is imperative that the recruitment and intervention 
commence much earlier in the third trimester of pregnancy.   
5.3.4 Pragmatic design 
A pragmatic approach is based on the fact that the ‘traditional criteria for scientific 
validity do not in themselves guarantee usefulness to practitioners’ (Worren et al., 
2002, p. 1228).  As such, even if results can be produced in a laboratory, these results 
do not necessarily translate into knowledge that is applicable in real-life settings and 
useful for improving clinical practice.  A pragmatic approach is used to determine 
whether an intervention will be successful when implemented under normal 
circumstances (Peat, 2001; Steen & Roberts, 2011).  This study design adopted a 
pragmatic approach to research.  
Initially, in the planning stages of this study, consultation was completed with the 
microbiology department of the St. George/Sutherland hospitals.  During this 
consultation period, a variety of swab collection and testing techniques were 
explored to determine the level of GBS and Lactobacilli counts in women’s vaginas.  
One option that was explored was testing vaginal swabs with polymerase chain 
reaction (PCR). PCR is a technique that amplifies the DNA sequences of a sample to 
accurately identify the presence of specific organisms (Edwards et al., 2008). This 
would be the most sensitive and accurate form of testing to investigate the micro 
flora present in a woman’s vagina.  The major drawback of this testing is the cost.  
This method would also have required the researcher to collect every vaginal swab 
from every participant. This would have been logistically very difficult to achieve.  It 
also would have increased the invasiveness of the study sampling methods, as 
research indicates that women prefer to collect their own vaginal swabs (Mercer et 
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al., 1995; Price et al., 2006).  Despite these drawbacks, PCR still does remain a 
possible option for future research studies. 
After the microbiology consultation, and in light of the drawbacks, a more basic, 
pragmatic approach was agreed upon.  It was decided to utilise the study site’s 
standard collection and testing techniques for GBS vaginal swabbing for the research 
project.  By doing so, the project was able to take advantage of the GBS vaginal 
swab results routinely collected by all pregnant women at the study site at 
approximately 36 weeks gestation.   
The concerns that arose through using this approach revolved around the concepts of 
consistency and specificity.  The routine practice at the study site was that each 
pregnant woman collected her own vaginal swab at a gestation of approximately 
36 weeks.  Self-collection is considered less invasive and has been shown to be 
preferable to women (Mercer et al., 1995; Price et al., 2006). This called into 
question the consistency of the swabbing collection techniques, since each woman 
would collect her swab in a slightly different way.  One manner in which this issue 
was addressed was through consistent information distribution.  In the antenatal 
clinic, an informative brochure about GBS, including instructions on how to collect a 
vaginal swab, was given to every woman when it was necessary for them to complete 
the swab.  This information allowed for a degree of consistency in swabbing 
techniques with the different participants.   
In addition to consistent information distribution, each participant not only collected 
her routine vaginal swab at 36 weeks but also self-collected her final vaginal swab 
for the purposes of the study.  This procedure allowed for a degree of internal 
consistency because each individual participant collected both her own swabs. 
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The second concern with the pragmatic approach was the specificity of the testing 
techniques.  The results of the standard vaginal swab testing at the microbiology labs 
of the study site only specify the presence of a light, moderate or heavy growth of 
GBS.  They do not give numerical quantities.  They also only report on the presence 
of commensals, or normal vaginal flora, without specifying the identity of the flora.  
This lack of specificity did not allow for the study to monitor any subtle changes in 
the colonisation rates of vaginal GBS in the participants.  
In defence of this choice, clinically, medical professionals are only concerned with 
the presence or absence of GBS.  They are not concerned with the specific quantities.  
Therefore, in order to make the results of this study immediately relevant in the 
clinical setting, which is the basis of a pragmatic approach, the study also only 
focused on the presence or absence of GBS and the presence or absence of 
commensals. 
Although the pragmatic approach raised concerns regarding the consistency of swab 
collection techniques among the participants and regarding the specificity of the GBS 
results, it did utilise the standard processes undertaken at the study site.  Since these 
standard processes were used, it made the results immediately applicable, relevant 
and understandable in the clinical setting to the clinicians who would be utilising 
such information.  As such, though the pragmatic approach limits the results of the 
study, this approach can also be considered a strength of the research design.  The 
design flexed to work within the context of the clinical setting, instead of 
manipulating the clinical setting to accommodate the study. 
5.4 Strengths of the study 
Despite the lack of positive results and the limitations of this research, strengths also 
exist.  The major strength of this study is its contribution to the growing body of 
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knowledge supporting the safety of probiotic use in later pregnancy.  The other 
strengths are that it continues to justify the further investigation of the benefits of 
probiotic use on vaginal GBS in pregnancy and it aids in the development of future 
research designs.  The following sections discuss these points in further detail. 
5.4.1 Safety considerations 
The lack of adverse events noted in this study with probiotic use in the third trimester 
of uncomplicated pregnancies is a major strength of this study.  The safety indicators 
utilised in this study were adapted from the indicators used in two systematic reviews 
conducted on the safety of probiotic use in pregnancy (Allen et al., 2010; Dugoua et 
al., 2009). 
The results showed that there were no differences between the intervention and 
control groups with respect to the safety indicators investigated at and around the 
time of birth.  These safety indicators included birth weight, gestation at birth, mode 
of delivery, pre-labour spontaneous rupture of membranes and infant concerns post 
birth.  The only significant result that was produced in the statistical analysis was that 
women in the control group underwent assisted deliveries more often than women in 
the probiotics group.  Assisted deliveries include instrumental deliveries and 
emergency caesarean sections.  The significance remained even when the 
participants were limited to nulliparous women, who research indicates have a 
greater incidence of assisted delivery (Baskett et al., 2008).  As mode of delivery was 
one of the safety indicators, the higher probability of achieving a normal birth in the 
probiotics group further supports the safety of the intervention. 
The second set of data collected investigating the safety of the intervention was 
through a follow-up telephone survey at approximately six months after the birth of 
each of the participant’s infants.  All 34 of the participants participated in the survey.  
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Not one was lost to follow-up.  The survey found that no differences existed between 
the two groups relating to the overall health of the infants of the study participants at 
six months of age.  These findings further support the evidence that probiotic use in 
later pregnancy produces no adverse events in healthy women experiencing 
uncomplicated pregnancies. 
5.4.2 Justification for further research 
Another strength of this study is it suggests further research in this area may be 
justified.  Commensals can be defined as normal vaginal micro flora, such as 
Lactobacilli (Barrons & Tassone, 2008; Lagenaur et al., 2011b; Rose et al., 2012).  
The significant presence of commensals in the vaginas of participants who had taken 
daily probiotics positively reflects on the potential of probiotics to impact vaginal 
GBS.  The justification for this study was based on multiple, consistent research 
findings which found that women with higher vaginal colonisations of Lactobacillus 
are more likely to have no detectable vaginal GBS colonisations (Altoparlak et al., 
2004; Donders et al., 2000; Kubota et al., 2002; Takeyoshi et al., 2002; Whitney et 
al., 2004).  This finding from the current study supports the possibility that the 
consumption of oral probiotics can result in the colonisation of the vagina with 
Lactobacillus.  This increases the potential then, in turn, to reduce or eradicate the 
presence of GBS from the vagina.  The door is still wide open for further research on 
the use of probiotics to impact vaginal GBS. 
5.4.3 Assistance in the development of study designs 
This study’s significant finding of commensals in the vaginas of women who had 
consumed probiotics, as discussed in the previous section, leads us on to the study’s 
third strength.  This strength is the information that this research provides in aiding 
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the development of future study designs.  Since this study had the unexpected finding 
of showing an increase of vaginal commensals with probiotic use, future design 
recommendations would include the presence of commensals as a research indicator.  
They would also revolve around strategies for increasing the commensal 
colonisations to a point where they can compete with and impact upon vaginal GBS.  
These strategies, as discussed earlier in this chapter, include increasing the length of 
the intervention, increasing the dose of the intervention and possibly changing the 
species of Lactobacillus used.   
This study was always intended to be a pilot project.  It was developed to be the 
initial research attempt for the purpose of testing the viability of this study design for 
future research.  As such, this project fulfilled its purpose.  It was successful in 
generating valuable information to help guide the actions of future researchers in 
their design attempts.  
5.5 Conclusion 
In conclusion to the discussion chapter, the aim of this study was to complete a pilot 
project to ascertain if the research design was appropriate to determine whether a 
daily oral dose of probiotics can reduce the rate of vaginal group B streptococcal 
(GBS) colonisation in pregnancy.  This research study has contributed valuable 
information that has added to the growing body of knowledge around probiotic use in 
pregnancy.  It did generate multiple avenues of exploration for future research.  
These avenues include research designs which incorporate longer intervention times, 
higher probiotic doses and different probiotic strains.  These future designs may also 
incorporate larger sample sizes, different sampling techniques and different swab 
testing techniques.  Many possibilities for future research are apparent from this pilot 
project. 
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In addition, a major strength of the current study was that its findings have provided 
further support for the safety of probiotic use in later pregnancy by healthy women 
experiencing normal pregnancies.  All the findings of this study coincide to declare 
that the opportunity still remains for future research to uncover the preventative 
potential of probiotics for vaginal GBS in pregnancy. 
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6  CONCLUSION 
6.1  Introduction 
The final chapter of this thesis reiterates the findings of the study in light of the 
original aim of the study: to complete a pilot project to determine if the research 
design of this study was appropriate to determine if a daily oral dose of probiotics 
can reduce the rate of vaginal group B streptococcal (GBS) colonisation in 
pregnancy.  This chapter also reflects on the study’s success at achieving this aim.  It  
summarises the potential reasons for the lack of a reduction in vaginal GBS with oral 
probiotic use that was seen in this study.  This chapter also presents the implications 
this study has for future research projects as well as for clinical practice.   
6.2 Summary of findings 
The main finding of the study was that there was no significant difference in vaginal 
GBS colonisation rates in women who had consumed a daily oral dose of probiotics 
as compared to women who had not.  This lack of significant difference remained 
even when a subgroup analysis was performed including only those participants who 
had consumed 14 days or more of probiotics.  One unexpected finding from the 
subgroup analysis was that significantly more women who had taken probiotics had 
commensals colonising their vaginas (p=0.048).  Commensals are normal vaginal 
flora, such as Lactobacilli (Barrons & Tassone, 2008; Lagenaur et al., 2011b; Rose et 
al., 2012). 
Another significant finding was that there were no differences between the probiotics 
group and the standard care group with respect to the safety indicators investigated.  
This lack of difference in the safety indicators was present throughout all stages of 
the research trajectory, including the antenatal period, labour and birth, the postnatal 
period and six months post birth.   
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6.3 Achievement of study aims 
The hypothesis of the study asked the question: if Lactobacillus colonisation rates 
can be increased in pregnant women’s vaginas, could this result in a decrease in 
group B streptococcal (GBS) colonisation rates? The aim of the study was to pilot 
the appropriateness of this research design to determine whether a daily oral dose of 
probiotics can reduce the rate of vaginal group B streptococcal (GBS) colonisation in 
pregnant women. 
As stated in section 6.2, ‘Summary of findings’, no significant difference was found 
in vaginal GBS colonisation between the participants who consumed daily oral doses 
of probiotics and those who were in the control group.  Even though there was a lack 
of positive results, this study still attained its aim.  The study was investigating the 
appropriateness of this specific research design in addressing the question raised by 
the hypothesis.  The investigation has shown that this is not an effective study design 
to trial the impact of oral probiotics on vaginal GBS colonisation.   
However, this research, through its design, has laid foundational groundwork for 
future research.  The main drawback of the study design was the length of 
intervention.  Only seven of the 21 women recruited to the probiotics group were 
successful in completing the entire three-week intervention.  This limitation was due 
to the uncontrollable nature of labour and birth and the late gestation at which 
women were recruited.  This is one obvious area which has the opportunity to be 
addressed with future research and already the findings have been disseminated 
through national and international conferences (Appendix I).  Other areas that may 
have contributed to the lack of positive results were a potentially inadequate 
probiotic dosage and a potentially incorrect probiotic strain. 
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6.4 Recommendations for future research 
The finding of significantly more women who had consumed 14 or more days of 
probiotics with vaginal commensal colonisation when compared to the control group 
continues to support the potential of oral probiotics to impact the vaginal micro 
environment.  Future research possibilities exist investigating the impact of 
probiotics with longer intervention times, higher doses of probiotics and different 
strains of probiotics.  Future research should plan to recruit women at an earlier 
gestation in their pregnancies.  Future designs may also incorporate larger sample 
sizes, different sampling techniques and different swab testing techniques.  Many 
possibilities for future research are apparent from this pilot project. 
6.5 Implications for clinical practice 
The major implication for clinical practice that has arisen through this research is it 
has provided further evidence to support the lack of adverse events with probiotic use 
in later pregnancy by healthy women experiencing normal pregnancies.  Even though 
no significant positive results were obtained through this specific research study, the 
potential of probiotic use in pregnancy remains.  This project continues to reinforce 
the use of probiotics by pregnant women if they choose to pursue this avenue of 
health.  Due to the results of this study, clinicians can support women in these 
choices with reduced concerns about the safety of probiotic use in later pregnancy.  
6.6 Final remarks 
Although this pilot project did not succeed in providing evidence that oral probiotic 
usage in pregnancy can impact vaginal GBS colonisation, it did achieve its piloted 
aim, which was to determine the validity of the study design used.  This aim was 
achieved in this thesis by highlighting the limitations in the study design, which will 
aid in guiding the development of future research designs.  The results of this study 
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did not close the door on the potential use of probiotics to impact vaginal GBS, but 
rather opened the opportunity for future research in this field.  The opportunity still 
remains for research to uncover the preventative potential of probiotics for vaginal 
GBS in pregnancy. 
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The hospital is doing research to try and answer this question: 
Can Probiotics Improve the Bacteria in your Vagina? 
  20% of pregnant Australian women have a bacteria in 
their vaginas called Group B Streptococcus (GBS) 
 GBS does not hurt the women but  babies who are  
infected during labour and birth can become seriously ill 
 We are seeking to find out if a daily oral dose of 
probiotics can prevent this infection 
 You can be involved if you are over 18 yrs old, are having 
a normal healthy pregnancy, and have been found to 
have GBS in your vagina at 36 weeks pregnant 
 If you are interested in participating in this research, then 
please talk to your doctor or midwife 
 
Appendices 
  94 




PARTICIPATION INFORMATION SHEET FOR PREGNANT WOMEN 
 
Title: Study Investigating the Impact of Oral Probiotic Use on Vaginal Group B 
Streptococcal Rates in Pregnant Women: A Pilot Randomised Controlled Study 
 
Purpose of the Research 
   
This is an invitation to participate in a study conducted by a Master’s Research 
Student (Paula Olsen), under the supervision of experienced researchers, at the 
University of Wollongong.  The purpose of this research is to determine if taking a 
certain strain of oral probiotics can decrease the number of pregnant women with a 
bacterial colonisation called Group B Streptococcus (GBS) in their vaginas.  
Probiotics are live micro-organisms that pass on a health benefit to the person taking 
them. GBS infections may cause serious illness in some newborn babies.  If this 
study is successful it will show that there may be a way to prevent GBS colonisation 
of the vagina.  It could then become the basis of a larger research study in order to 




Paula Olsen                                            Dr Moira Williamson                   Professor Don 
Iverson               Dr Chris Georgiou 
Registered Midwife/Masters Student     Health & Behavioural Sciences    Pro Vice-
Chancellor (Health)   IHMRI/Grad School Medicine 
                                            (02) 4221- 3381                            (02) 4221- 
4677                         (02) 4222-5000 
Pgc589@uow.edu.au                             moiraw@uow.edu.au                   daynah@uow.edu.au                 
georgiou@uow.edu.au 
 
Demands on Participants 
 
If you decide to be involved in the research you will be randomly chosen to either 
continue with your standard antenatal care or continue with your standard care plus 
to take the oral probiotics Lactobacillus Rhamnosus GR-1 and Lactobacillus Reuteri 
RC-14 daily for three weeks from about the thirty-sixth week of your pregnancy.  
 
You will also be required to participate in a telephone survey when your baby is 6 
months old. This survey should take about 10 minutes of your time.  
 
Possible Risks, Inconveniences and Discomforts 
 
If you are randomly chosen to be in the probiotics group, you will have the 
inconvenience of taking oral probiotics daily for three weeks. The probiotics will be 
provided to you free of charge.  All participants will be required to collect an 
additional vaginal swab at about 39 weeks pregnant.   
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There is a small chance that probiotics can cause some infections; these infections 
generally only occur in people who have underlying chronic illnesses. There is no 
expected risk to your baby.  Research studies have been done testing probiotics in 
pregnancy.  Most of these studies have been different from this current study because 
they have investigated whether taking probiotics in pregnancy can reduce the 
chances of infants developing allergies.  None of these studies have reported any 
adverse events from the probiotics.  The specific strains of probiotics to be used in 
this study have not previously been tested in pregnancy.  They have been tested in 
healthy women who are not pregnant and have resulted in no adverse events.  These 
strains are theoretically safe for use in pregnancy but their absolute safety has not yet 
been proven through research studies.  The follow-up telephone survey will help to 
prove the safety of these probiotics by providing the researchers with the chance to 
ask questions about the well-being of yourself and your baby after being involved in 
the study.   
 
It is current hospital policy that all women found to have GBS in their vaginas 
receive intravenous antibiotics in labour.  This is an initial study to test if probiotics 
have any impact on GBS in vaginas. As a result, all women participating in the 
research will still be encouraged to have intravenous antibiotics in labour in 
accordance with current hospital policy. Any results from this study will not alter the 
treatment you will receive during your pregnancy or your labour. 
  
Your involvement is completely voluntary and you are free to withdraw your 
participation and your information at any time.  If you choose not to participate or 
choose to withdraw from participation this will not impact the care you receive 
during your pregnancy at the Sutherland Hospital.  All information gathered 
throughout the research will be kept strictly confidential. 
 
Funding and Benefits of the Research 
 
The funding for this research is being provided by the Edith Cavell Trust.  If 
probiotics are found to reduce the rate of GBS in pregnancy this will give women a 
possible strategy to prevent GBS vaginal colonisation.  It also may decrease the 
number of women receiving intravenous antibiotics in labour as a result reducing the 
number of newborns exposed to this bacterium.  This study will provide preliminary 
evidence on which to base a larger, more definitive research study.  
 
Ethics Review and Complaints 
 
This study has been reviewed by the Human Research Ethics Committee of the 
University of Wollongong.  If you have any concerns or complaints regarding the 
way this research has been conducted, you can contact the University of 
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Women at 33 weeks gestation attending the antenatal clinic at Sutherland Hospital all receive a research study brochure and 
participant information sheet 
 
Women at 36 weeks gestation routinely self-collect lower vaginal swab. The swab is returned to the doctor or midwife at the 
clinic. 
 
Researcher telephone contact to invite women to  
participate . 
GBS -ve 
No further contact by researcher. 
Interested women approached at next antenatal visit by researcher – informed consent obtained – randomised into control or 
intervention group. 
At 39 weeks both groups repeat lower vaginal swab. 
Standard care plus daily oral dose of probiotics for 3 weeks. 
GBS +ve 




Data Analysis after birth 
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8.4 Appendix D: Participant data collection sheet 
 
Probiotics and GBS Research Form 
 
Coding #________________________________________ 
Date of entry____________________________________ 
MRN___________________________________________ 
EDC____________________________________________ 





Past hx of GBS_____________________________________ 
 
RESEARCH GROUP  (Please Circle) 
 
 STANDARD CARE PLUS PROBIOTICS 
 STANDARD CARE 
 
Did you take any antibiotics during the trial period? For how long? 
__________________________________________________________ 
Were you able to take the probiotics every day? How many days 
were missed?  
__________________________________________________________
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Pregnancy & Birth  
 








Given antibiotics while in labour (why or why not)? 
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8.5 Appendix E: Consent form 
 
 
CONSENT FORM FOR PREGNANT WOMEN 
 
The impact of oral probiotic use on vaginal Group B Streptococcal rates in 
pregnant women: a pilot randomised controlled study 
 
Researcher: Paula Olsen 
 
I have been given information about “The impact of oral probiotic use on the vaginal 
Group B Streptococcal rates in pregnant women” and discussed the research project 
with the researcher.  I understand that Paula Olsen is conducting this research as part 
of a Master of Midwifery (Research) degree and is being supervised by Dr Moira 
Williamson, Professor Don Iverson and Dr Chris Georgiou from the University of 
Wollongong.   
 
I have been advised of the potential risks and burdens associated with this research, 
which includes the possible inconvenience of taking a daily dose of oral probiotics 
for three weeks.  It has been explained to me that there is an extremely low risk of 
developing some form of infection from the probiotics and these infections generally 
only occur in people with underlying chronic illness.  There is no anticipated risk to 
myself or my developing infant. I have had the opportunity to contact Paula Olsen 
with any questions I may have about the research and my participation.  
 
I understand that my participation in this research is voluntary, I am free to refuse to 
participate and I am free to withdraw from the research at any time. My refusal to 
participate or withdraw consent will not affect the care I receive during my pregnancy 
at Sutherland Hospital in any way. 
 
If I have any enquiries about the research, I can contact Paula Olsen on  
and Dr Chris Georgiou on (02) 4222-5000 or if I have any concerns or complaints 
regarding the way the research is or has been conducted, I can contact the Ethics 
Officer, Human Research Ethics Committee, Office of Research, University of 
Wollongong on 4221 4457. 
 
By signing below I am indicating my consent to:  
 
• being randomly chosen to either continue with the standard antenatal care or to 
receive standard care plus taking orally the probiotic strains Lactobacillus 
Rhamnosus GR-1 and Lactobacillus Reuteri RC-14 for three weeks from 
approximately 36 weeks gestation. 
 
I understand that the data collected from my participation will be used for a thesis, 
journal articles, conference presentations and a larger research study.  I consent for it 
to be used in these manners.  I understand that my identity will not be disclosed 
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Signed       Date 
 
.......................................................................  ......./....../...... 
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Did you know… 
 
 The Sutherland hospital is doing research, in collaboration with 
IHMRI, into whether oral probiotics can prevent Group B Streptococcus 
from colonising pregnant women’s vaginas 
 
 If your vaginal swab result at 36 weeks shows that you have Group B 
Streptococcus you may receive a phone call from a researcher to see if 
you would be interested in being involved in this study. 
 
 If you receive a phone call and do NOT want to be involved just tell 
the researcher.  You will not be contacted again and it will not impact 
the care you receive at the clinic in any way. 
 
 If you would like to be involved, the researcher will meet with you 
the next time you are at the hospital.  You will be able to ask the 
researcher any questions you may have at this time.   
 
 Women who would like to be involved will be randomly chosen either 
to continue with the usual antenatal care or to continue with the usual 
antenatal care & receive an oral dose of probiotics daily for three 
weeks.  All women who are involved will then recollect their own 
vaginal swab at 39 weeks into the pregnancy.  
 
Appendices 
  102 
8.7 Appendix g: Follow-up telephone survey at six months 
 




Hello, may I speak to _____________ please?  It’s Paula Olsen calling.  You were 
involved in a research project at the Sutherland Hospital during your pregnancy.  I 
am just calling to ask some questions about you and your baby’s health over the past 
six months.  These questions should take about 10 minutes to answer.  Is this a 









How long was the baby exclusively breastfed for? 
 
Are there any smokers in the house? 
 
Do you keep any pets in the house? 
 
Does the baby go to child care? 
 





Did the baby have any health concerns at birth? 
 
How many times have you taken the baby to the GP? 
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Has the baby ever been hospitalised? 
 
Have you given any medications to your baby? 
 
Has the baby had any signs of allergies? Eczema? Asthma? Allergic Rhinitis? 
 
How would you describe your baby’s health? 
 Very healthy 
 Occasionally unwell 
 Nearly always unwell 
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8.9 Appendix I: Successful Conference Abstracts 
1. Asia Pacific midwives conference 2009, Hyderabad, India—oral 
presentation 
 
Developing Natural Ways for Preventing Group B Streptococcal Vaginal Infections 
in Pregnancy 
 
Group B Streptococcus (GBS) is an organism that has been recognized in the 
developed world since the 1970s as the leading cause of neonatal sepsis.  GBS 
infection is vertically transmitted from an asymptomatic mother to her infant during 
labour and birth.  Considering the serious consequences of neonatal GBS infection, 
strategies for prevention have so far focused on administration of antibiotics to 
women in last week of pregnancy or administering antibiotics during labour. 
 
The disadvantages of these strategies are the development of antibiotic resistance in 
GBS and non-GBS pathogens, the disruption of the colonization of the neonates’ gut 
with the appropriate flora, the risk of maternal anaphylaxis, the deficit in maternal 
knowledge regarding GBS and the medicalization of birth.  It is commonly 
understood that administering intravenous antibiotics in labour to prevent neonatal 
GBS is only an intermediate solution until better solutions are developed. 
 
In response to these facts and the seriousness of GBS infection, it becomes apparent 
that future research is necessary to determine natural ways of increasing 
Lactobacillus colonisations in women’s vaginas in order to decrease GBS 
colonisation rates and to protect their infants from exposure to GBS infections.  This 
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2. Australian College of Midwives National Conference 2011, Sydney, 
Australia— Poster presentation 
The impact of oral probiotic use on vaginal Group B Streptococcal colonisation rates 
in pregnant women: A pilot randomised controlled study 
 
Background 
Group B Streptococcus (GBS) is the leading cause of bacterial infections in the 
neonate in the developed world. This bacterium is passed from a woman’s vagina to 
her new-born during the process of labour and birth, potentially causing pneumonia, 
septicaemia and meningitis in the infant.  In order to prevent neonatal GBS infections 
most hospitals have protocols in place that identify pregnant women at risk of 
infecting their new-borns and give these women intravenous antibiotics in labour to 
inhibit the transmission.  The disadvantages of intravenous antibiotics in labour are 
the development of antibiotic resistance in GBS and non-GBS pathogens, the 
inhibition of the colonisation of the new-born’s gut with the appropriate flora and the 
medicalisation of childbirth.  
It has been shown that women with higher colonisation of vaginal Lactobacillus are 
more likely to have no detectable vaginal GBS.  This raises the hypothesis: Would 
increasing the colonisation rates of Lactobacillus in pregnant women’s vaginas result 
in a decrease in GBS colonisation rates?  A pilot randomised controlled trial is 
proposed to determine if oral probiotics may be a strategy for decreasing GBS 
vaginal colonisation rates by increasing vaginal Lactobacillus rates. 
Methods 
A sample of thirty GBS positive pregnant women will be recruited.  The GBS status 
of these women will be determined by the routine lower vaginal swabs that are self-
collected by all women in the antenatal clinic at the proposed hospital site at thirty-
six weeks gestation.  These women will be randomised into control and intervention 
groups.  The control group will continue with standard care; the intervention group 
will receive standard care and take a daily dose of oral probiotics for three weeks.  
After three weeks both groups will repeat the self-collection of a lower vaginal swab.  
Appendices 
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It is anticipated that the data collection phase will take approximately three months.  
A telephone survey will be performed at six months postpartum in order to verify the 
safety of the intervention. 
Expected Outcomes 
It is expected that a significant number of women in the intervention group will be 
GBS negative after three weeks of oral probiotics when compared with the control.  
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3. Breathing New Life into Maternity Care conference 2012, Melbourne, 
Australia—poster presentation 
 
The impact of oral probiotic use on vaginal Group B Streptococcal colonisation rates 
in pregnant women: A pilot randomised controlled study 
Background 
Group B Streptococcus (GBS) is the leading cause of bacterial infections in the 
neonate in the developed world. This bacterium is passed from a woman’s vagina to 
her new-born during the process of labour and birth, potentially causing pneumonia, 
septicaemia and meningitis in the infant.  In order to prevent neonatal GBS infections 
most hospitals have protocols in place that identify pregnant women at risk of 
infecting their new-borns and give these women intravenous antibiotics in labour to 
inhibit the transmission.  The disadvantages of intravenous antibiotics in labour are 
the development of antibiotic resistance in GBS and non-GBS pathogens, the 
inhibition of the colonisation of the new-born’s gut with the appropriate flora and the 
medicalisation of childbirth.  
It has been shown that women with higher colonisation of vaginal Lactobacillus are 
more likely to have no detectable vaginal GBS.  This raises the hypothesis: Would 
increasing the colonisation rates of Lactobacillus in pregnant women’s vaginas result 
in a decrease in GBS colonisation rates?  A pilot randomised controlled trial is 
proposed to determine if oral probiotics may be a strategy for decreasing GBS 
vaginal colonisation rates by increasing vaginal Lactobacillus rates. 
Methods 
Thirty-five women found to have GBS colonisation in their vaginas at 36 weeks 
gestation were recruited into the study.  These women were randomised into control 
and intervention groups.  The control group continued with standard care and the 
intervention group continued with standard care in addition to receiving a daily oral 
dose of probiotics.  Three weeks after recruitment or while in labour, depending on 
which occurred first, a lower vaginal swab was collected.  These swabs were sent to 
pathology to be tested for the presence of GBS.  Six months post the birth of their 
infants, the participants then engaged in a follow-up telephone survey to determine 
the safety of the intervention. 
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 Outcomes 
The data analysis phase of the project is ensuing at the moment.  The results of these 
findings will be presented.  These results will include an emphasis on the safety of 
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4. International Confederation of Midwives conference 2014, Prague, 
Czechoslovakia—oral presentation 
 
The impact of oral probiotic use on vaginal Group B Streptococcal colonisation rates 
in pregnant women: A pilot randomised controlled trial 
 
Aim 
The main hypothetical question was: Can a daily oral dose of probiotics reduce the 
rate of vaginal Group B Streptococcal (GBS) colonisation in pregnancy?  The aim 
was to test the viability of this specific study design to address the hypothesis. 
 
Methodology  
A pilot randomised controlled trial was performed which recruited 34 GBS positive 
women at approximately 36 weeks pregnant.  The participants were randomly 
allocated to the control group, which continued with standard antenatal care, or to the 
intervention group, which continued with standard antenatal care and received a 
daily oral dose of probiotics for 3 weeks or until the birth of their infant.  A lower 
vaginal swab, to determine the presence of GBS, was collected 3 weeks post consent 
or when a participant was in labour.   
 
Results 
No significant difference was found in vaginal GBS between the control and 
intervention groups.  Only 7 of 21 in the intervention group completed the entire 21 
days of probiotics.  A sub-group analysis, including only those who had completed 
14 days or more of probiotics, also showed no significant difference in vaginal GBS 
when compared to the control.  It did show significantly more vaginal commensals in 
the probiotics group.   
 
Discussion 
There are 4 possible reasons for the lack of significant results: 
 The length of the intervention was too short. 
 The dosage of the probiotics was too low. 
 The wrong strain of probiotics was used. 
 Oral probiotics are ineffective at impacting vaginal GBS. 
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Implications 
The significant increase of vaginal commensals (normal vaginal flora, including 
Lactobacilli) in women who had completed 14 days or more of probiotics continues 
to support the potential of probiotics to impact GBS in pregnancy.  This pilot project 
supports the safety of probiotic use in later pregnancy.  Many possibilities remain for 
future research to further investigate the use of probiotics to impact vaginal GBS. 
 
 
